4ῃᾷ Cancer Asia Forum
Asian Challenges in Shifting the Disease Burdens-Global Health and Global Science-

Date: April 21, 2009, 13:00-16:00
Location: United National University, Elizabeth Hall

20th Asia Pacific Cancer Conference
Theme: Cancer Control - Setting the Focus on
Unique Asian Pacific Contributions
Date:November 12(Thu.)-14(Sat.), 2009
Venue: Tsukuba International Congress Center President: Hideyuki Akaza(Dept. of Urology, University of Tsukuba)

http://www.apcc2009.org/

4th Cancer Asia Forum
Asian Challenges in Shifting the Disease Burdens-Global Health and Global ScienceDate: April 21, 2009 1:00pm- 4pm
Location: United National University, Elizabeth Hall http://www.unu.edu/access/Meeting Outline

In Asian countries non contagious diseases such as diabetes, cancer, andcardiovascular diseases, are replacing once the frightening contagious diseases.
We are now facing the question what we can do in this shift of the disease
burdens in Asian allies.
To understand non-contagious diseases, following natural history of humandiseases is indispensable. However it demands long standing global scientificcooperation. In the scene, science is not only promoting clarity of the natural
history, but also setting a measure of communication and cooperation of people
in different background of culture and of overcoming conflicts of interests. In
this sense, the role of “sciences” is essential.
There are closely related but different subpopulations in Asian. Genetic
stratification of populations together with clinical epidemiological date will bringus to loosen disease burdens in Asia. The field Asia would be suitable toexamine hypotheses, which are generated in the studies of developed countries.
Extending the outcome of developed countries into Asian context will require
constructive global health policy among Asia allies.
Global health will reach the stage of science, which promoting cooperation ofresearchers, medical professionals and pharmaceutical domains, which willbring us to better communication and cooperation among Asian allies.

“Cancer Asia” Forum, Organization: Norie Kawahara╙ 4 ࿁ࠕࠫࠕ߇ࠎࡈࠜ࡯࡜ࡓ
‫ޟ‬Asian Challenges in Shifting the Disease Burdens‫ޠ‬ᣣᤨ:4 ᦬ 21 ᣣ 13:00-16:00
႐ᚲ:࿖ㅪᄢቇ ࠛ࡝ࠩࡌࠬࡎ࡯࡞㧔United National University, Elizabeth Hall㧕
http://www.unu.edu/access/1:00㧙1:10‫ࠬ࡞ࡋ࡞ࡃ࡯ࡠࠣޟ‬㧒ࠣࡠ࡯ࡃ࡞ࠨࠗࠛࡦࠬ‫ޠ‬ࠕࠫࠕ߇ࠎࡈࠜ࡯࡜ࡓ਎⹤ੱ ᴡේ ࡁ࡝ࠛ㧔᧲੩ᄢቇవ┵⑼ቇᛛⴚ⎇ⓥ࠮ࡦ࠲࡯)‫ ╙ޣ‬1 ㇱ Shifting the Disease Burdens in Asia‫ޤ‬

1:10㧙1:30․೎⻠Ṷ‫∛∔ߩࠕࠫࠕޟ‬᭴ㅧߩᄌൻ‫ޠ‬የり ⨃㧔⥄ᴦකᄢᢎ᝼ ฬ⹷਎⇇଻ஜᯏ㑐⷏ᄥᐔᵗ࿾ၞ੐ോዪ㐳㧕

1:30㧙1:40

⾰⇼ᔕ╵

1:40㧙1:50‫ޟ‬ᣣਛකቇߩㅴዷߦߟ޿ߡ‫ޠ‬೨↰ శ຦㧔ෘ↢ഭ௛⋭ஜᐽዪ߇ࠎኻ╷ផㅴቶ㐳㧕

1:50㧙2:00‫ޟ‬࿖㓙ක≮ㅪ៤߆ࠄߺࠆࠕࠫࠕ߇ࠎ⎇ⓥ‫ޠ‬㊁ፒᘕੳ㇢㧔㐳ፒᄢቇ࿖㓙ㅪ៤⎇ⓥᧄㇱ ᢎ᝼㧕

2:10㧙2:15

⾰⇼ᔕ╵ 2:15㧙2:25‫ޟ‬ᚒ߇࿖ߦ߅ߌࠆࠣࡠ࡯ࡃ࡞ࡋ࡞ࠬᚢ⇛⑳᩺‫ޠ‬⷏ጊ ᱜᓼ㧔ක⮎ᚢ⇛⎇ⓥᚲ ઍ⴫㧕

2:25㧙2:35‫⥃ࠎ߇ࠕࠫࠕޟ‬ᐥ⎇ⓥߩ⃻⁁ߣ੹ᓟ‫ޠ‬⿒ᐳ ⧷ਯ㧔╳ᵄᄢቇᄢቇ㒮⣢ᴲዩེ⑼ቇ࡮↵ᕈᯏ⢻⑼ቇᢎ᝼㧕

2:35㧙3:00

⾰⇼ᔕ╵‫ోޔ‬૕⸛⼏  ‫ ╙ޣ‬2 ㇱ Doing Science in Asia‫ޤ‬
3:00㧙3:10‫ޟ‬ᚒ߇࿖ߦ߅ߌࠆ࡜ࠗࡈࠨࠗࠛࡦࠬߩ⛔ว࠺࡯࠲ࡌ࡯ࠬ᭴▽ߦะߌߡ‫ޠ‬㊀⮮ ๺ᒄ㧔ౝ㑑ᐭ࡜ࠗࡈࠨࠗࠛࡦࠬᜂᒰෳ੐ቭ㧕

3:10㧙3:15‫ࠠࡦࠪ࡞ࡋޟ‬ት⸒ᡷ⸓ߩᗧ๧ߔࠆ߽ߩ‫ޠ‬Ⴧ੗ ᔀ㧔⁛┙ⴕ᡽ᴺੱක⮎ၮ⋚⎇ⓥᚲ㧕

3:15㧙3:30  ‫ޟ‬Pan-Asian SNP Initiative:ࠕࠫࠕੱߦࠃࠆ‫⸃ࡓࡁࠥࠕࠫࠕోޔ‬ᨆߩ⹜ߺ‫ޠ‬⩲㊁ ⚐ᄦ㧔᧲੩ᄢቇක⑼ቇ⎇ⓥᚲᢎ᝼㧕
3:30㧙3:50

⾰⇼ᔕ╵  ో૕⸛⼏

3:50㧙4:00

ࠛࡇࡠ࡯ࠣ 㤥Ꮉ ᷡ 㧔᡽╷⎇ⓥᄢቇ㒮ᄢቇ ᢎ᝼㧛․ቯ㕖༡೑ᵴേᴺੱᣣᧄක≮᡽╷ᯏ᭴ ઍ⴫ℂ੐㧕Meeting Agenda
13:00-13:10
Prologue: Global Health and Global Science.
Norie Kawahara, Project Researcher, Research Center for Advanced Science andTechnology, The University of Tokyo

Session 1: Shifting the Disease Burdens in Asia
13:10-13:30
Public Health Challenges in Asia.
Shigeru Omi, Professor, Jichi Medical University,
Regional Director Emeritus World Health Organization Regional Office for Western
Pacific

13:30-13:40
Question and Answer
13:40-13:50
Collaboration on Cancer Research Between Japan and China.
Mitsuya Maeda, Director, Cancer Control Office, Health Service Bureau, Ministry of
Health,Labour and Welfare

13:50-14:00
Asian Cancer Research in Asian International Collaboration.
Shinjiro Nozaki, Professor and Vice Director, Center for International Collaborative
Research, Nagasaki University

14:10-14:15
Question and Answer
14:15-14:25
New Platform of Global Health in Japan.
Masanori Nishiyama, Representative Director, Research Institute of Strategy on
Medicines

14:25-14:35
Asian Cancer Clinical Research: Present Status and Problem of Asian Cooperation.
Hideyuki Akaza, Graduate School of Comprehensive Human Sciences, Tsukuba
University

14:35-15:00
Question and Answer, Discussion
Session 2: Doing Science in Asia
15:00-15:10
To Construct a Sustainable Infrastructure of Integrative Bioinformatics
Network for Life Science Research in Japan.
Kazuhiro Shigetoh, Director for Life Sciences, Council for Science and Technology Policy,
Cabinet Officeᴾ
15:10-15:15
Recent Amendments of Helsinki Declaration – the Era of Human Subject Research.
Tohru Masui, Chief, National Institute of Biomedical Innovation,
Department of Bioresources Research

15:15-15:30
Pan-Asian SNP InitiativeᾉAsian Whole Genome SNP Analysis by ourself.
Sumio Sugano, MD Professor, Laboratory of Functional Genomics, Department ofMedical Genome Sciences, Graduate School of Frontier Sciences, The University ofTokyo

15:30-15:50
Question and Answer, Discussion
15:50-16:00
Epilogu.
Kiyoshi Kurokawa, Professor, National Graduate Institute for Policy Studie  Chairman, Health Policy Institute, Japan䈏䉖ኻ╷ၮᧄᴺ

╙㧠࿁ࠕࠫࠕ߇ࠎࡈࠜ࡯࡜ࡓ

䈏䉖ኻ╷䉕✚ว⊛䈎䈧⸘↹⊛䈮ផㅴ䈏䉖੍㒐෸䈶ᣧᦼ⊒⷗䈱ផㅴ

࿖
䶙
䷛
ኻ
╷
ផ
ㅴ
ද
⼏
ળ

Collaboration on Cancer
Research Between Japan And
China䂾 䈏䉖੍㒐䈱ផㅴෘ↢ഭ௛ᄢ⤿䂾 䈏䉖ᬌ⸻䈱⾰䈱ะ਄╬䈏䉖ኻ╷ផㅴၮᧄ⸘↹᩺䈱૞ᚑ䈏䉖ක≮䈱ဋ䈩䉖ൻ䈱ଦㅴ╬䂾 ኾ㐷⊛䈭⍮⼂෸䈶ᛛ⢻䉕᦭䈜䉎කᏧ䈠䈱ઁ䈱ක≮ᓥ੐⠪䈱⢒ᚑ䈏䉖ኻ╷ផㅴၮᧄ⸘↹㑑⼏᳿ቯ䊶࿖ળႎ๔䂾 䈏䉖ᖚ⠪䈱≮㙃↢ᵴ䈱⾰䈱⛽ᜬะ਄䂾 䈏䉖ක≮䈮㑐䈜䉎ᖱႎ䈱෼㓸ឭଏ૕೙䈱ᢛ஻╬

ㅪ៤ᐔᚑ䋲䋱ᐕ䋴᦬䋲䋱ᣣ࿾ᣇ౏౒࿅૕

᳃⎇ⓥ䈱ផㅴ╬

ㇺ㆏ᐭ⋵䂾 䈏䉖䈮㑐䈜䉎⎇ⓥ䈱ଦㅴ䂾 ⎇ⓥᚑᨐ䈱ᵴ↪

ㇺ㆏ᐭ⋵䈏䉖ኻ╷ផㅴ⸘↹ෘ↢ഭ௛⋭ஜᐽዪ䈏䉖ኻ╷ផㅴቶ㐳
೨↰ శ຦

࿖

䂾 ක≮ᯏ㑐䈱ᢛ஻╬䂾 ක⮎ຠ෸䈶ක≮ᯏེ䈱ᣧᦼᛚ⹺䈮⾗䈜䉎ᴦ㛎䈱ଦㅴ䈏䉖ක≮䈱ឭଏ䈱⁁ᴫ╬䉕〯䉁䈋╷ቯ䂾 ⥃ᐥ⎇ⓥ䈮ଥ䉎ⅣႺᢛ஻

2

߇ࠎኻ╷੍▚㗵ߩផ⒖ߦߟ޿ߡ䈏䉖ኻ╷ផㅴၮᧄ⸘↹䋨න૏䋺ం౞䋩㪊㪇㪇ో䈩䈱ᖚ⠪䊶ኅᣖ䈱቟ᔃ䈏䉖䈮䉋䉎ᱫ੢⠪䈱ᷫዋ
䋨20%ᷫ䋩

ෘ↢ഭ௛⋭䋨ᣥෘ↢⋭䋩㪉㪌㪇ో䈩䈱䈏䉖ᖚ⠪䊶ኅᣖ䈱⧰∩䈱シᷫ䊶≮㙃↢ᵴ䈱⾰䈱ะ਄



㪉㪇㪇


 



㪈㪌㪇

㪈㪇㪇


㊀ὐ⊛䈮ข䉍⚵䉃䈼䈐੐㗄
䈏䉖䈱
ᣧᦼ⊒⷗
ฃ⸻₸
䋵䋰䋦

䈏䉖䈱
੍ 㒐
ᧂᚑᐕ⠪
䈱༛ᾍ₸
䋰䋦

ᴦ≮䈱ೋᦼᲑ㓏䈎䉌䈱✭๺䉬䉝䈱ታᣉ

᡼኿✢≮ᴺ䊶ൻቇ≮ᴺ䈱ផㅴ䇮䈖䉏䉌䉕ኾ㐷⊛䈮ⴕ䈉කᏧ╬䈱⢒ᚑ䈜䈼䈩䈱᜚ὐ∛㒮䈪䇸᡼኿✢≮ᴺ䊶ᄖ᧪ൻቇ≮ᴺ䇹䉕ታᣉ䈜䈼䈩䈱䈏䉖⸻≮䈮៤䉒䉎කᏧ䈮✭๺䉬䉝䈱ၮᧄ⊛䈭⎇ୃ䉕ታᣉ䈏䉖⊓㍳䈱ផㅴ
㒮ౝ䈏䉖⊓㍳䉕ⴕ䈉ක≮ᯏ㑐ᢙ䈱Ⴧടක≮ᯏ㑐䈱ᢛ஻╬

㪌㪇
㪇

䈏䉖ක≮
䈮㑐䈜䉎
⋧⺣ᡰេ䊶
ᖱႎឭଏ


䌓㪌㪐㵭







䌓㪍㪉㵭

䌈䋲㵭

䌈䋵㵭

ኻ䈏䉖10䉦ᐕ✚วᚢ⇛䋨䌓59ᐕᐲ䌾䌈5ᐕᐲ䋩䌈䋶㵭 

䌈䋹㵭

䌈㪈㪉㵭



䌈㪈㪌㵭

䌈㪈㪍㵭

䈏䉖స᦯ᣂ10䈎ᐕᚢ⇛䋨䌈6ᐕᐲ䌾15ᐕᐲ䋩䈜䈼䈩䈱䋲ᰴක≮࿤䈮
⋧⺣ᡰេ䉶䊮䉺䊷
䉕⸳⟎䈚䇮⎇ୃ䉕ୃੌ䈚䈢⋧⺣ຬ䉕㈩⟎߇ࠎߩ࿷ቛ≮㙃࡮✭๺ࠤࠕߩలታ‫ޛ‬ం౞‫ޜ‬߇ࠎ੍㒐࡮ᣧᦼ⊒⷗ߩផㅴߣ߇ࠎක≮᳓Ḱဋߡࠎൻߩ
ଦㅴ‫ޛ‬ం౞‫ޜ‬࡮߇ࠎኾ㐷ක╬߇ࠎක≮ኾ㐷 ࡮ࠗࡦ࠲࡯ࡀ࠶࠻ࠍᵴ↪ߒߚኾ㐷කߩ⢒ᚑࠬ࠲࠶ࡈߩ⢒ᚑ⊖ਁ౞
⊖ਁ౞

࡮㒮ౝ߇ࠎ⊓㍳ߩផㅴ⊖ਁ౞࡮߇ࠎߦ㑐ߔࠆ᥉෸໪⊒ផㅴ੐ᬺ⊖ਁ౞

࡮߇ࠎኾ㐷ක⥃ᐥ⎇ୃࡕ࠺࡞ ࡮߇ࠎක≮ߦ៤ࠊࠆකᏧߦኻߔ
੐ᬺࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᛛⴚ⎇⊖ਁ౞ୃ⊖ਁ౞࡮࿖㓙౒หᴦ㛎෸߮ᣂ⮎ߩᣧᦼᛚ⹺╬ߩផㅴ
࡮ක≮↪㤗⮎ㆡᱜ૶↪ផㅴ੐ᬺ
⊖ਁ౞
⊖ਁ౞
࡮࿷ቛࡎࠬࡇࠬࠤࠕ⎇ୃ╬⚻⾌⊖ਁ౞䈏 䉖 ⎇ ⓥ3䌈㪈㪐㵭‫ޛ‬ం౞‫ޜ‬࡮߇ࠎ⸻≮ㅪ៤᜚ὐ∛㒮ᯏ⢻ ࡮߇ࠎක≮ߦ៤ࠊࠆකᏧߦኻߔ
ᒝൻ੐ᬺࠆ✭๺ࠤࠕ⎇ୃ⊖ਁ౞⊖ਁ౞

ේೣ䇮䈜䈼䈩䈱䋲ᰴක≮࿤䈮᜚ὐ∛㒮䉕⸳⟎䈚䇮䋵ᄢ䈏䉖䈱࿾ၞㅪ៤䉪䊥䊁䉞䉦䊦䊌䉴䉕ᢛ஻䌈㪈㪏㵭࡮࿷ቛ✭๺ࠤࠕኻ╷ផㅴ੐ᬺ
⊖ਁ౞

䌈㪉㪇㵭

㪟㪉㪈㩾

㶎ᐔᚑ䋱䋸ᐕᐲ䈲䇮⵬ᱜ੍▚䈮䋱䋵ం౞䉕⸘਄䇯㶎ᐔᚑ䋲䋰ᐕᐲ䈲䇮⵬ᱜ੍▚᩺䈮 䋸ం౞䉕⸘਄䇯䂾ᐔᚑ䋲䋱ᐕᐲ੍▚᩺䈱ਥ䈭੐ᬺ䈮䈧䈇䈩
᡼኿✢≮ᴺ෸߮ൻቇ≮ᴺߩ
ផㅴਗ߮ߦߎࠇࠄࠍኾ㐷⊛ߦⴕ߁කᏧ╬ߩ⢒ᚑ‫ޛ‬ం౞‫ޜ‬䌈㪈㪎㵭╙䋳ᰴኻ䈏䉖㪈㪇䈎ᐕ✚วᚢ⇛䋨䌈㪈㪍ᐕᐲ䌾㪉㪌ᐕᐲ䋩߇ࠎ⊓㍳ߩផㅴ࡮߇ࠎ⊓㍳ߩታᣉߦ㑐ߔࠆ⺞ᩏ ࡮⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ⾌
⊖ਁ౞࡮♖ᐲ▤ℂ‫ޔ‬ᜰዉߩታᣉ
⊖ਁ౞ ࡮䈏䉖ᬌ⸻ฃ⸻ଦㅴડᬺㅪ៤ᆔ⸤
੐ᬺ
279⊖ਁ౞
࡮߇ࠎᬌ⸻ฃ⸻₸ะ਄ડᬺㅪ៤ផ
ㅴ੐ᬺ
⊖ਁ౞
࡮ᅚᕈߩஜᐽᡰេኻ╷ᆔ⸤੐ᬺ⊖ਁ౞
࡮੃߇ࠎ↪ࡑࡦࡕࠦࠗ࡞✕ᕆᢛ஻੐ᬺ⊖ਁ౞
࡮߇ࠎኻ╷ᖱႎ࠮ࡦ࠲࡯⚻⾌⊖ਁ౞߇ࠎߦ㑐ߔࠆ⎇ⓥߩផㅴ‫ޛ‬ం౞‫ޜ‬࡮╙㧟ᰴኻ߇ࠎ✚วᚢ⇛⎇ⓥ⚻⾌⊖ਁ౞࡮߇ࠎ⎇ⓥഥᚑ㊄⊖ਁ౞࡮࿾⃿ⷙᮨ଻ஜ⺖㗴ផㅴ⎇ⓥ⚻⾌⊖ਁ౞
࡮࿖┙߇ࠎ࠮ࡦ࠲࡯⥃ᐥ㐿⊒࠮ࡦ࠲࡯⚻⾌⊖ਁ౞

䇸䈏䉖ኻ╷ផㅴၮᧄ⸘↹䇹䈮䈍䈔䉎୘೎⋡ᮡਥ䈭⎇ⓥ䈱᭎ⷐ䋨䋱䋩߇ࠎ⎇ⓥ࡮䈏䉖䈮䉋䉎ᱫ੢⠪䈱ᷫዋ䇮䈜䈼䈩䈱䈏䉖ᖚ⠪෸䈶䈠䈱ኅᣖ䈱⧰∩䈱シᷫਗ䈶䈮≮㙃↢ᵴ䈱⾰䈱⛽ᜬะ਄䉕ታ⃻䈜䉎䈢䉄䈱䈏䉖ኻ╷䈮⾗䈜䉎⎇ⓥ䉕䉋䉍৻ጀផㅴ䇯䇼䋱䇽ᣣਛਔ࿖䉕฽䉃᧲䉝䉳䉝⻉࿖䈮䈍䈔䉎䈏䉖ኻ╷䈱⾰ะ਄䈫ᮡḰൻ䉕⋡ᜰ䈚䈢⺞ᩏ⎇ⓥ䋨ᗲ⍮⋵䈏䉖䉶䊮䉺䊷⎇ⓥᚲ ↰ਛㇱ㐳䋩䂾ᐔᚑ䋲䋰ᐕᐲ䈎䉌ታᣉ䂾䉝䉳䉝࿾ၞ䈮․ᕈ䈱䈅䉎ⷐ࿃䈫䈏䉖䈫䈱㑐ㅪ䈮㑐䈜䉎⛔ว⸃ᨆ䊶ᣢሽᄢⷙᮨ䉮䊖䊷䊃䈱᛽಴䈫ㆬቯ䇮ෳടᗧᔒ䈱⏕⹺㸢ᣣᧄ䋷䉮䊖䊷䊃䋨⚂䋳䋸ਁੱ䋩ਛ࿖䋵䉮䊖䊷䊃䋨⚂䋳䋳ਁੱ䋩㖧࿖䋳䉮䊖䊷䊃䋨⚂䋱䋰䋰ਁੱ䋩䉟䊮䊄䋲䉮䊖䊷䊃䋨⚂䋲䋲ਁੱ䋩䇮䉲䊮䉧䊘䊷䊦䋱䉮䊖䊷䊃䋨⚂䋶ਁੱ䋩䊋䊮䉫䊤䊂䉞䉲䊠䋱䉮䊖䊷䊃䋨⚂䋲ਁੱ䋩
5䌾䈏䉖ኻ╷ផㅴၮᧄ⸘↹䈱⋡ᜰ䈜䉅䈱䌾ਥ䈭⎇ⓥ䈱᭎ⷐ䋨䋲䋩䇼䋲䇽ᣣਛ㑆䈮䈍䈔䉎䈏䉖䈱੍㒐䊶ᬌ⸻䊶⸻ᢿ䊶ᴦ≮䈱ะ਄䈱䈢䉄䈱⺞ᩏ⎇ⓥ䋨࿖┙䈏䉖䉶䊮䉺䊷䈏䉖੍㒐䊶ᬌ⸻⎇ⓥ䉶䊮䉺䊷 ੗਄ቶ㐳䋩䂾ᐔᚑ䋲䋱ᐕᐲ䈎䉌ታᣉ䂾ᚒ䈏࿖䈮䈍䈔䉎૞ᬺ䉼䊷䊛䉕✬ᚑ䊶䈏䉖⛔⸘ᜂᒰ
䊶䈢䈳䈖ኻ╷ᜂᒰ䊶䈏䉖∉ቇ⎇ⓥᜂᒰ䊶䈏䉖㑐ㅪᗵᨴ∝ᜂᒰ
䊶ⅣႺ⊒≸‛⾰ᜂᒰ䂾ਛ࿖⸰໧䈮䉋䉎ኾ㐷ኅ䈫䈱ᖱႎ੤឵䈮䉋䉍䇮ਔ࿖䈱ታᘒ䈮㑐䈜䉎ᖱႎ䉕෼㓸䂾ኾ㐷ൻ䉕᜗䈇䈢࿖㓙䉲䊮䊘䉳䉡䊛䈱㐿௅

6߇ࠎᖚ⠪ࠍ฽߼ߚ࿖᳃߇‫ޔ‬ㅴⴕ࡮ౣ⊒ߣ޿ߞߚ᭽‫∛ߩࠎ߇ߥޘ‬ᘒߦᔕߓߡ‫ޔ‬቟ᔃ࡮⚊ᓧߢ߈ࠆ߇ࠎක≮ࠍฃߌࠄࠇࠆࠃ߁ߦߔࠆߥߤ‫ޔ‬‫ࠍࠎ߇ޟ‬⍮ࠅ‫ߣࠎ߇ޔ‬ะ߈ว޿‫⽶ߦࠎ߇ޔ‬ߌࠆߎߣߩߥ޿␠ળ‫ޠ‬ߩታ⃻ࠍ⋡ᜰߔ‫ޕ‬7䉝䉳䉝䈏䉖࿖㓙౒ห⎇ⓥ䈱⃻⁁• ࿖䊧䊔䊦䈪䈱ข䉍⚵䉂• ᳃㑆࿅૕䈪䈱ข䉍⚵䉂╙䋴࿁䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛䉝䉳䉝䈏䉖⥃ᐥ⎇ⓥ䈱⃻⁁䈫੹ᓟ– NCCN 䈱႐ว• ડᬺਥዉ– ࿖㓙䋨䉝䉳䉝䋩౒หᴦ㛎

April21,2009• ੹ᓟ䈱࿷䉍ᣇ䈫⺖㗴࿖ㅪᄢቇ䊶䉣䊥䉱䊔䉴䊖䊷䊦⿒ᐳ ⧷ਯ╳ᵄᄢቇᄢቇ㒮
䌕䌔
DRAFT

䌕䌔
DRAFT

“ᣣᧄ࿖ෘ↢ഭ௛⋭䈫ਛ⪇ੱ᳃౒๺࿖ⴡ↢ㇱ䈫ⴡ↢䈍䉋䈶කቇ⑼ቇ䈮㑐䈜䉎දജⷡᦠ”ᣣਛ㖧ਃ࿖଻ஜᄢ⤿ળว• ྾䋩 දജ䈱ㅴⴕᐲ䈮ᔕ䈛䇮ో૕䉕⛔᜝䈜䉎䊥䊷䉻䊷䇮䉮䊮䉺䉪䊃䊌䊷䉸䊮෸䈶ฦಽ㊁䈱ᜂᒰ⠪䉕ቯ䉄䉎䇯ᵴേ⸘↹䈮䈲䇮෺ᣇ䈱ౕ૕⊛䈭දജ㗄⋡෸䈶⽷ോⷙቯ䉕฽䉃䇯⸳⟎䈘䉏䈢૞ᬺ䉼䊷䊛䈲䇮ዋ䈭䈒䈫䉅ੑᐕ䈗䈫䈮৻ᐲ䈱ળ⼏䉕ⴕ䈉䇯

䌕䌔
DRAFT

䌕䌔
DRAFT

Science Inner World ⸥੐
APCC (3rd Asia Cancer Forum 2009/2/7 ࿖ㅪᄢቇ)Japanese Cancer Scientists Plan Asia-Pacific Research Network
TOKYO—International health organizations have long recognized the devastating impact of infectious
diseases such as HIV/AIDS ------"Cancer is expected to become more serious in middle- and low-income countries,
yet it has not attracted sufficient global attention," Hajime Inoue, director ofinternational cooperation for Japan's ministry of health told the Third Cancer Asia
Forum on 7 February here. ------While cancer is a global problem, solutions have to be local. "The epidemiology of cancer in
Asia and in the West is very different," said Hideyuki Akaza, a urologist at University ofTsukuba in Japan. He explained that because of genetic and dietary factors, certain cancers
are more prevalent in Asia than in the West and the response to treatment varies. Yet limited
clinical trial data has hindered the development of evidence-based guidelines for cancer carein Asia, he said. ------

To fill the gap, researchers are eyeing a network modeled on the United States'
National Comprehensive Cancer Network (NCCN), through which 21 leading
American cancer centers collaborate to conduct research and develop clinical careguidelines. -------

䌕䌔
DRAFT

Asia/NCCNCollaboration

䌕䌔
DRAFT

Collaboration• EarlyinNCCNhistory,wewerenotsure
whetherdiversecomprehensivecancer
centerswouldbeabletoagreeonhowto
treatcancers.
• EarlyinourcollaborationswithAsian
physicians,wewerenotsurehowwellourpracticeswouldmeshwiththoseofourAsiancolleagues.
• Today,withsomeexperienceweare
confidentthatwewillreachconsensus
䌕䌔
DRAFT

• Trustiskey• Highqualitytranslationmakesunderstandingpossible• Broaderliteratureisconsidered• Wehavediscoveredareaswherethereare
differencesinourapproaches.
– Sometimestheyaretheresultofdifferentnationalcarepatterns– Sometimestheyaredifferentapproachesdrivenby
specialtyconsiderations
䌕䌔
DRAFT

Authorization

1stNCCNAsiaScientificSymposiumReport• NCCNauthorizesselectedexpertgroupstodevelopAsianThoughtLeaderStatementsaboutitsClinicalPractice
Guidelinestoreflectgeneticvariationsinmetabolismof
agentsand regulatoryenvironmentsofhostcountries.
• TheStatementsaresubjecttoapprovalbyNCCNand
representativesofNCCN’s diseaseͲspecificpanels.

Since 2006, NCCN has been in close collaboration with Chinese oncology
experts headed by Dr. Yan Sun in developing the China edition of the NCCN
Guidelines. This project achieved huge success in China, and is under
rapid expansion. In making full use of the present opportunity for summit
discussion, this symposium especially incorporated panel meetings of
NCCN experts and Chinese experts to update the China versions ofavailable NCCN Guidelines as well as develop new NCCN Guidelines.
Experts from China paid high attention to the development of NCCN
Guidelines that are especially tailored to China’s situation. Their intense
research on relevant clinical evidence before the meeting and lucid
presentation of their viewpoint and findings during the discussion gainedwide recognition from NCCN Panel Members. The resulting updated China
editions of NCCN Clinical Practice Guidelines in Oncology™, createdthrough the joint efforts of Chinese experts and NCCN experts, shall be
instrumental in pushing forward the standardization of clinical oncology
practice in China.
www.nccn.org/international/pdf/Synopsis_1st_NCCN_Asia_Symposium_Report_KS%20_2.pdf

䌕䌔
DRAFT

䌕䌔
DRAFT

䌕䌔
DRAFT

䌕䌔
DRAFT

NCCN RCC Asian Consensus Statement Committee Meeting
Beijing, China March 28, 2009

䌕䌔
DRAFT

䌕䌔
DRAFT

ObjectiveandProcedureof
AsianStatement
• Objective:– Raisetheproblems– Findthewaytosolve• Procedure:
1.Specifyandcollecttheproblems
2.Selectandproviderelevantsolution
3.Sortouttheevidencesandrecommendationby
assignedpanelmembers
䌕䌔
DRAFT

䌕䌔
DRAFT

PubMedSearch
Total6180forRCCintheworld
No Asian literature is cited.

䌕䌔
DRAFT

Number of manuscript

2003

709

2004

989

2005

975

2006

1067

2007

1226

2008

1175

2009
Total

39
6180 (1201; Asia)

䌕䌔
DRAFT

ExamplesofAsian,Globalclinical
trialincludingJapanNumberofliteraturesofclinicalstudyinAsiancountries• China• India• Japan• Korea

Year

4
1
24
4

䉝䉳䉝⊒䈱䊧䊔䊦䈱㜞䈇⥃ᐥ⹜㛎䈏ᄢ䈇䈮ਇ⿷䈚䈩䈇䉎䇯
࿖䊧䊔䊦
᳃㑆䊧䊔䊦
ડᬺ䊧䊔䊦
䌕䌔
DRAFT

䌕䌔
DRAFT

Temsirolims (CCIͲ779)
AsiancollaborativePIIstudy

Temsirolims (CCIͲ779)
AsiancollaborativePIIstudy

Study Outline

Study Outline

Phase, Design

Phase II, Open Label

PurposeTo evaluate the safety, efficacy andpharmacokinetics of temsirolimus in Asianpatients with advanced renal cell
carcinoma

Target Number
80of PtsLocations

Study Duration

Primary
Outcome
Measures• Rate of Adverse Events• Clinical Benefit Rate
(CR+ PR+ SD>24 wks)

Secondary
Outcome
Measures• Progression Free Survival• Duration of Response• Overall Survival• Pharmacokinetics• Japan (18 sites)• Korea (4 sites)• China (8 sites)
June 2007 – On going(Pt enrollment has been completed)
䌕䌔
DRAFT

Everolimus (RAD001)
International collaborative PIII study

䌕䌔
DRAFT

StudyConduct

ProgressionͲFreeSurvivalbyTreatment
CentralRadiologyReview

Stratification• Prior VEGFr
TKI: 1 or 2

• MSKCC risk group:favorable, intermediate,or poor

2:1

100

Everolimus + BSC(n = 277)
277)

Hazard ratio = 0.33
95 % CI [0.25, 0.43]80
Probability, %N = 416

R
A
N
D
O
M
I
Z
A
T
I
O
N

Upon
DiseaseProgression
Placebo + BSC(n = 139)Median PFS
Everolimus: 4.90 mo
Placebo: 1.87 mo

60

Log rank P value = <0.001
Everolimus (n = 277)
Placebo (n = 139)

40
20

Safety Interim
analysis

2nd Interim
analysisdata cut-off:
15 OCT 2007,
N=410

End of double
blind analysis
data cut-off: 28
FEB 2008• 416 patients randomized between December 2006 and November 2007
• Analysis cut-off: February 28, 2008, based on 266 PFS events• 2nd interim analysis based on cut-off:15 October 2007, efficacy boundary crossed with 410 patients /191 PFS events (Motzer et al., Lancet 2008), complete study unblinded on February 28, 2008䌕䌔

DRAFT

0
0
Patients at risk
Everolimus 277
Placebo
139

2

4

6

8

10

12

14

26
2

10
0

1
0

0
䌕䌔
0DRAFT

Months
192
47

115
15

51
6

Everolimus (RAD001)
International collaborative PIII study

Participatingcountries
Australia: I. Davis, H. Gurney, K. Pittman,

Pazopanib

D. Goldstein, P. Mainwaring
Canada: J. Knox, S. Ades, T. Cheng,
S. Hotte,
Y.-J. Ko, M. MacKenzie, S. North

US: N. Gabrail, L. Appleman,
D. George, J. Hamm, A. Hussain,
J. Hajdenberg, N. Vogelzang,
T. Logan, J. Beck, K. Rathmell,
P. Lara, A. Dudek, M. Gordon,
T. Anderson, M. Danso,
W. Berry, R. Gersh, G. Guzley,
D. Loesch, D. Schlossman,
D. Smith

France: A. Caty, F. Rolland,
C. Chevreau, B. Kuclos,S. Negrier

Spain: F. deMuro, M. Climent,
D. Castellano, E. Calvo, P. Maroto

A Study of Pazopanib versus Sunitinib in
the Treatment of Subjects with Locally
Advanced and/or Metastatic Renal Cell
Carcinoma (Study VEG108844)

Germany: J. Gschwend, P. Albers,
L. Bergmann, J. Beck

Poland: C. Szczylik, J. Pikiel,
A. Pluzanska, R. Zdrojowy
Netherlands: S. Osanto, C. Van Herpen,
F. Van den Eertwegh, G. Groenewegen

Italy: E. Bajetta, F. Boccardo, R. Passalacqua,
C. Sternberg, G. Carteni, P. Conte

Japan: N. Shinohara, N. Tsuchiya, H. Akaza,
H. Fujimoto, M. Niwakawa, H. Uemura, H.
Kanayama, M. Eto, Y. Sumiyoshi, T.
Tsukamoto, M. Usami, A. Terai, Y. Hamamoto,
M. Maruoka

Novartis Study Team

䌕䌔
DRAFT

ᴦ㛎䈱᭎⇛

䌕䌔 26
DRAFT

࿖೎䈱⋡ᮡ∝଀ᢙ• ኻ⽎䋺 ೨ᴦ≮ᱧ䈱䈭䈇ㅴⴕ䊶ォ⒖ᕈ⣢⚦⢩≸ᖚ⠪• ᴦ㛎䊂䉱䉟䊮䋺 ᄙᣉ⸳౒ห䇮㕖⋤ᬌ䇮ή૞ὑൻ䇮╙㸉⋧⥃ᐥ⹜㛎• ᛩਈᣇᴺ䋺 Pazopanib䋻 1ᣣ1࿁ᛩਈ

Sunitinib䋻 1ᣣ1࿁4ㅳ㑆ᛩਈ䈱ᓟ䇮2ㅳ㑆ભ⮎• ਥⷐ⹏ଔ㗄⋡䋺 ήჇᖡ↢ሽᦼ㑆䋨PFS䋩
Pazopanib 800 mg 1ᣣ1࿁⚻ญᛩਈㅴⴕ䊶 ォ⒖ᕈ⣢⚦⢩≸ⵍ㛎⠪ᢙ䋺 876଀North America䉝䊜䊥䉦䋺 373଀
䉦䊅䉻䋺
58଀

Europe䉟䉩䊥䉴䋺 125଀䊄䉟䉿䋺40଀䉴䊕䉟䊮䋺 38଀䉥䊤䊮䉻䋺 35଀䉟䉺䊥䉝䋺 30଀䍏䍐䍷䍵䍻䍢䍼䋺 20଀䍛䍑䍈䍎䍡䍼䍻䋺 15଀

(Pazopanib䋺Sunitinib=1䋺1)

Asia/Pacific
ᣣᧄ䋺
50଀
ਛ࿖䋺
30଀
㖧࿖䋺
20଀
บḧ䋺
10଀
䍓䍎䍛䍢䍵䍶䍏䋺 32଀⋡ᮡ∝଀ᢙ䋨ว⸘䋩䋺 876଀
ෳട࿖ᢙ䋺
14䊰࿖

Sunitinib 50 mg 1ᣣ1࿁⚻ญᛩਈ
䌕䌔 27
DRAFT

䌕䌔 28
DRAFT

ComparisonofAEsbetweenJapanandEU/USA
Sunitinib

Thrombocytopenia
Japanese
N=81

GIST䋧RCC䋨Japan䋩䋬n=81

Solid tumors䋨EU/US䋩䋬
n=450

Grade 3/4䋬n (%)

Grade 3/4䋬n (%)

Plt

35 (43.2)

16 (3.6)WBC

13 (16.0)

18 (4.0)-20

Neutro38 (46.9)

28 (6.2)-30

Ly

26 (32.1)

0Hg

11 (13.6)

4 (0.9)lipase26 (32.1)

25 (5.6)

AST(GOT)

6 (7.4)2 (0.4)-70

ALT(GPT)

5 (6.2)3 (0.7)-80P

10䋨12.3䋩

0Amylase7 (8.6)

11 (2.4)

EU/USAᲢEU/USAᲢN=450)

Plateletcount
0

CBC

(%)

-10

-40
-50

Chemistry

-60

C1D1
䌕䌔
DRAFT

ᴦ㛎䉇ડᬺਥዉ䈱⥃ᐥ⹜㛎䈱໧㗴ὐ䈫කᏧਥዉ౒ห⎇ⓥ䈱࿷䉍ᣇ

D14

D28

D42 (C2D1)
䌕䌔
DRAFT

C: Cycle, D: Treatment days from initiation of the drug

CancerincidenceinJapanesemigrantstoHawaii.

• ડᬺਥዉ⥃ᐥ⹜㛎– ⹜㛎ⅣႺ䈏ᢛ䈦䈩䈇䉎• ⎇ⓥ⾗㊄䇮ੱ⊛⾗Ḯ䇮⹜㛎ⅣႺ– ⹜㛎䊂䉱䉟䊮䈮೙⚂• ડᬺ䈱೑ኂ

• කᏧਥዉဳ⥃ᐥ⹜㛎– ⌀䈮ᔅⷐ䈭⹜㛎䊂䉱䉟䊮䈏น⢻
– ⾗㊄
– ⵬ఘ

July 2004
䌕䌔
DRAFT

䌕䌔
DRAFT

CancerControl–
CancerControl–SettingtheFocusonUniqueAsianPacific
Contributions䋻ProstateCancerPrevention
EpidemiologicalStudy

Decrease of Incidence
and mortality
Industrialization

Elimination of the Risk Factors

Education
Basic Study of Cancer Prevention

Publicannouncement
FeasibilityStudy(phaseII)

Phase III Study

䌕䌔
DRAFT

䉁䈫䉄
䉝䉳䉝࿖㓙౒ห⹜㛎• ⣲≌㗔ၞ䈮䈍䈔䉎䉝䉳䉝䉕ਛᔃ䈫䈚䈢౒ห⹜㛎䈱䈎䈢䈤
1. ⵾⮎ડᬺ䉕ਛᔃ䈫䈚䈢᛫≸ᣂ⮎䈱㐿⊒⹜㛎
2. කᏧਥዉဳ䈱⥃ᐥ⹜㛎
3. ࿖䋨᡽ᐭ䋩䈏ਥዉ䈜䉎൮᜝⊛౒ห⎇ⓥ૕೙• ⃻ᤨὐ䈪䈲䇮䋱䋮䈱䉂䈏Ⓙ௛䉕੺䈚䈢䈫䈖䉐䇮䋲䋮䋳䈮䈧䈇䈩䈲੹ᓟ䈱㊀ⷐ䈭⺖㗴䈪䈅䉎• 䉝䉳䉝䈫䈇䈦䈩䉅᭽䇱䈭ੱ⒳䊶ᢥൻ䊶⚻ᷣ– 䈬䈱䉋䈉䈮䉁䈫䉁䉎䈎䋿– 䈬䈱䉋䈉䈮䉁䈫䉄䉎䈎䋿– 䈬䈱䉋䈉䈭⚵❱૞䉍䈏น⢻䈎䋿– ᣣᧄ䈱૏⟎䈨䈔䈲䋿
䌕䌔
DRAFT

⛔ว䊂䊷䉺䊔䊷䉴᭴▽䈱ᔅⷐᕈ䇼⃻⁁䇽䇼⛔ว䊂䊷䉺䊔䊷䉴᭴▽䈮ะ䈔䈢⺖㗴䇽䊶 䊤䉟䊐䉰䉟䉣䊮䉴ಽ㊁䈮䈍䈇䈩䇮䉭䊉䊛⸃ᨆ䊒䊨䉳䉢䉪䊃䉇䉺䊮䊌䉪3000䊒䊨䉳䉢䉪䊃╬ᄙ㊂䈱䊂䊷䉺⫾Ⓧဳ䈱⎇ⓥ੐ᬺ䉕ᄙᢙታᣉ䇯╙㧠࿁ࠕࠫࠕ߇ࠎࡈࠜ࡯࡜ࡓ䊶 ੹ᓟ䈱䊤䉟䊐䉰䉟䉣䊮䉴⎇ⓥ䈱ផㅴ䉇ᣂ䈢䈭↥ᬺ䈱ഃ಴䈱䈢䉄䈮䈲↥↢䈘䉏䈢䊂䊷䉺䈱ᵴ↪䈏ਇนᰳ䇯ᚒ߇࿖ߦ߅ߌࠆ࡜ࠗࡈࠨࠗࠛࡦࠬߩ䊶 ⃻࿷䇮↥಴䈘䉏䈢䊂䊷䉺䈮䈧䈇䈩䈲ฦ⎇ⓥ䊒䊨䉳䉢䉪䊃Ფ䈮䊂䊷䉺䊔䊷䉴䉕⛽ᜬ䊶▤ℂ䇯⛔ว࠺࡯࠲ࡌ࡯ࠬ᭴▽ߦะߌߡ䊶 䈠䈉䈚䈢䊂䊷䉺䊔䊷䉴䈱⚿วൻ䈲ᢛ஻ㅜ਄䈮䈅䉍䇮⎇ⓥ䊒䊨䉳䉢䉪䊃䈫䈚䈩ታᣉ䇯䊶 䉒䈏࿖䈱⎇ⓥ㐿⊒ၮ⋚䈱䈘䉌䈭䉎ᒝൻ䈱䈢䉄䇮⎇ⓥ䈱ᚑᨐ䈫䈚䈩䇮↥಴䈘䉏䈢䊂䊷䉺䉕೑↪⠪䈱ⷞὐ䈮┙䈦䈩⛔วൻ䈚䇮ല₸䉋䈒⎇ⓥ⠪䇮↥ᬺ⇇䇮䈘䉌䈮䈲࿖᳃䈮ㆶర䈚䈩䈇䈒䇮⛔ว䊂䊷䉺䊔䊷䉴䈱᭴▽䈏ᔅⷐ䇯䊶 ᕡਭ⊛䈭䊂䊷䉺䊔䊷䉴䈱⛽ᜬ䊶▤ℂ䈱੍▚ភ⟎䈏䈫䉌䉏䈩䈇䈭䈇䈢䉄䇮䊒䊨䉳䉢䉪䊃⚳ੌᓟ䈮䇮ᢔㅺ䈚䈩䈚䉁䈉䈖䈫䈏ෂᗋ䈘䉏䉎䇯࿖ኅ⊛៊ᄬ䈮䈧䈭䈏䉍䈎䈰䈭䈇䇯䇼ฦ࿖䈱⛔ว䊂䊷䉺䊔䊷䉴䈱⁁ᴫ䇽䇼䉭䊉䊛䊶䊘䉴䊃䉭䊉䊛ਥⷐ䊒䊨䉳䉢䉪䊃䈱᭎ⷐ䇽⇘ ⇴∆ ∝ ∃⇟ ⇮⇘ ⇴∆ɼᙲ ⇽∓ ⇞⇍ ⇕⇮Ӹ૨ ᢿᅹ ‫ ܖ‬Ⴞ⇘⇴ ∆⇳ ⇩⇮ ∕∞ ⇕

࠰›‣ ․ › ‣ ‥ ›‣ …

ࡇ
›‣ ‧

›‣

›‣

NCBI 䋨National Center for Biotechnology Information䋩䋺䊶੍▚䋺⚂䋸䋰ం౞ 䋨䋲䋰䋰䋶ᐕ䋩䊶ੱຬ䋺⚂䋴䋰䋰ฬ䊶ㆇ༡ᒻᘒ䋺ᩮ᜚ᴺ䈮ၮ䈨䈐NLM䋨☨࿖࿖┙කቇ࿑ᦠ㙚䋩੍▚䈪ㆇ༡
EBI (European Bioinformatics Institute)䋺
䊶੍▚䋺⚂䋴䋵ం౞ (䋲䋰䋰䋶ᐕ䋩䊶ੱຬ䋺⚂䋳䋰䋰ฬ䊶ㆇ༡ᒻᘒ䋺EMBL*䈏ඨಽ⽶ᜂ䇮ᱷ䉍䈲ᄖㇱ⾗㊄ᢡˡ ‫↝ ܇‬ႆ ྵᛦ ራೞ Ꮱ↚ ᧙↾ ↺ዡ ፠ ႎ↙ ᚐௌɼ ᙲ ⇥ ∙ ⇷ ⇕ ឋ ኖ ‥ • •• ᆔ ↝ ؕ ஜ ನ ᡯ ӏ ↢ ↌ ↝ ೞ Ꮱ ᚐ ଢᢡˡ ‫׹ ٶ܇‬ᄂ ᆮ⇸ ⇮ ⇘ ⇴ ∆ ᢡ ˡ ‫ ܇‬᪸ ؏ ɶ ↝ ⁅ ⁀⁂᧙ ᡲ ऴ ‫ ↝ إ‬ӕ ࢽ ↗ ᚐ ௌ⇬∞ ∏∞ ∇⇊ ⇯Ҕ ၲ ܱྵ ҄

ኖ ‥• ɢ ʴ ↝ ⁅⁀⁂ ↗ ᕤ д ↝ ј ௐ ⅚ и ˺ ဇ ↙ ↘ ↗ ↝ ᧙ ̞ ᚐ ଢྸᄂ ⇘⇴ ∆⅚ ౡཋ⅚ ᢡˡ ‫׹ ٶ܇‬⇸ ⇮ ⅚ ∄ ⇌ ⇟ ⅚ ౡ ཋ ↝ ⇘ ⇴ ∆ ⅚ ⁕ ‶⁀ ″ ᚐ ௌ ⅚ ᢡ ˡ ‫ ׹ ٶ ܇‬ᚐ ௌ⇶⇊ ⇐⇊ ∙ ⇻ ⇏ ∄ ⇬ ⇉ ⇕ ⇟ᄂ ᆮဃԡ ᅹ ‫ܖ‬Ў ᣼↝ ؕ࠴ ⇭∞ ⇥⇿ ∞⇟ ↝ ನሰ ∝᭗ ࡇ҄ወӳ ⇭∞ ⇥ ⇿∞ ⇟ဃ ԡ ᅹ ‫ ܖ‬Ў ᣼ ‶‴ ৆ ဦ ᇌ క ૅ ੲ ⅚ ∃ ∞ ⇥ ∑ ⇛ ⇊ ⇮ ૢ ͳኺ ฎင ಅ Ⴞ⇭∞ ⇥⇿ ∞⇟ ኽӳ⇘⇴ ∆ऴ ‫إ‬ወ ӳ‫ ܦ‬μ ᧈ ⁕ ‶⁀ ″ౝ㑑ᐭෳ੐ቭ䋨䊤䉟䊐䉰䉟䉣䊮䉴ᜂᒰ䋩㊀⮮ ๺ᒄ䇼᰷☨䈱ઍ⴫⊛䈭⛔ว䊂䊷䉺䊔䊷䉴䇽⇽∓ ⇞⇍ ⇕⇮↝ಒ ᙲ› ‣‪䊒䊨䉳 䉢䉪䊃䊂 䊷䉺䊔䊷 䉴䈱Ⴧ ᄢ Ⴧ ട⇥ ∙ ⇷ ⇕ ‥ • ••ᐔᚑ䋲䋱ᐕ䋴᦬䋲䋱ᣣ‫׎‬ϋ ‫↝ ٳ‬ஊ ဇ↙ ⇸⇮ ⇘⇴ ∆᧙ ᡲऴ ‫⅚ إ‬ᚐ ௌ⇣ ⇻⇮ ↝ወ ӳႎ ૢͳ
ኖ ‥ɢ ↝ ⇸ ⇮ ↝ μ ᧈ ⁕ ‶⁀ ″ ᣐ З ऴ ‫ ↝ إ‬ӕ ࢽ ↗ ᚐ ௌဃཋ ⇝⇟ ⇬∆ Сࣂ ؕ Ⴔ২ ᘐоᕤ ૅ ੲ↝ ↎↰ ↝⇘ ⇴∆ ⅚⇥ ∙⇷ ⇕ ⅚҄ ӳཋ ɟᝦ ᚐௌ ২ᘐ ᧏ႆဃ˳ ᭗Ў ‫܇‬ᇌ ˳ನ ᡯᐏ⇥ ∙ ⇷⇕ ឋӏ ↢᧙ ᡲᙐ ӳ˳ ↝ᇌ ˳ ನᡯ ∝ೞ Ꮱᚐ ଢᖨႉ ឋೞ Ꮱᚐ ௌ‫ ܦ‬μ ᧈ ⁕ ‶ ⁀″ ↝ ᢡ ˡ ‫ ܇‬ႆ ྵ ᫁ ࡇ ↙ ↘ ‫ ૾ ٶ‬᩿ ⅺ ↸ ↝ ೞ Ꮱ ᚐ ௌᢡˡ ‫ ٶ܇‬ಮࣱ ∈⇭ ∑ ᚐௌ⇸⇮ ↝ ∈⇭ ∑၌ ध↚ ᧙↾ ↺ᢡ ˡ‫׹ ٶ ܇‬ऴ ‫ ↝إ‬ӕࢽ ↗ᚐ ௌ೅ แ ⁅⁀ ⁂ᚐ ௌଐஜʴᨼ‫ׇ‬ҽ ဃі ΁ Ⴞ၌ ध⇘ ⇴∆ ⇭∞ ⇥⇿ ∞⇟‪ʴ ↚ ᧙ ↈ ↺ ⁅ ⁀ ⁂‣ ‧ ɢ ᆔ ↝ ⇈ − ∑ ᫁ ࡇ ↝ ᚐ ௌ

ⅻ ⇂ ሁ ‧ ၌ ध ↝ ⇘ ⇴ ∆ ∕ ⇊ ⇯ ↙ ⁅⁀⁂ ᚐ ௌ ↙ ↘ ↝ ⇭ ∞ ⇥ ⇿ ∞ ⇟ ҄⇮ ⇓⇝ ⇙⇘ ⇴∅ ⇕⇟ᢡˡ ‫ ܇‬ႆྵ ᚐௌ ↚↷ ↺⇘ ⇴∆ −⇿ ∑ ↖↝ ൒ࣱ ႆྵ ೞನ ᚐଢ၌ ध᧙ ᡲᖨ ႉឋɼᙲ ၌ ध⇁ ‫ݣ‬ᝋ ↗ↆ ↎၌ ध᧙ ᡲ↎ ⇂ ↠ⅾ ឋ↝ ੕ኧ ⅚ӷ ‫ܭ‬ᠾ ௎൦ င Ⴞ⇊ ⇳⇘ ⇴∆⇊⇳ ⇘ ⇴∆ ᣐЗ ↝ᚐ ᛠⅹ ↷↢ ᢡˡ ‫↝ ܇‬ೞ Ꮱᚐ ଢܼ အ⇘ ⇴∆⇼ ⇥ ↝ ⁕‶ ⁀″ ᣐ З ऴ ‫ ⅚ إ‬ႆ ྵ ᫁ ࡇ ⅚ ∄ ∞ ⇑ ∞ ऴ ‫ ↝ إ‬ӕ ࢽ ↗ ᚐ ௌᖛ ↝ ⇘ ⇴ ∆ ⅚ ⁕‶ ⁀ ″ ᣐ З ऴ ‫ ⅚ إ‬ᡲ ᦋ ‫ ׋ ע‬ऴ ‫ ↝ إ‬ӕ ࢽ ↗ ᚐ ௌᖛ ⇘⇴ ∆
ᠾ௎൦ ငဃ ཋ⇘ ⇴∆ ऴ‫ إ‬ወӳ‶‴ታ ✢ 䈲 䊂䊷䉺↢↥ ဳ䇼ᣣᧄ䈱ઍ⴫⊛䈭⛔ว䊂䊷䉺䊔䊷䉴䇽ᢥㇱ⑼ቇ⋭䈱⛔ว䊂䊷䉺䊔䊷䉴䋨䊤䉟䊐䉰䉟䉣䊮䉴⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋩䊶੍▚䋺⚂䋱䋱ం౞ 䋨䋲䋰䋰䋸ᐕ䋩䊶ੱຬ䋺䋲䋸ੱ䊶ㆇ༡ᒻᘒ䋺ᢥㇱ⑼ቇ⋭ᆔ⸤䊒䊨䉳䉢䉪䊃䈪ታᣉ⇊⇳ ↌ ↝˂ ᠾ௎ ൦င ဃཋ ወӳ ⇘⇴ ∆ ⇭∞ ⇥⇿ ∞⇟ ↝ૢ ͳ䋼䊤䉟䊐䉰䉟䉣䊮䉴PT䋺 ⵬ቢ⊛⺖㗴䇸↢๮⑼ቇ䊂䊷䉺䊔䊷䉴⛔ว䈮㑐䈜䉎⺞ᩏ⎇ⓥ䇹 ᄢਭ଻౏╷ ⊒⴫⾗ᢱ ᐔᚑ20ᐕ5᦬7ᣣ ᛮ☴䋾

㪈㪀㩷

ᐔᚑ
㪈䋷ᐕᐲ

ᐔᚑ
㪈䋸ᐕᐲ

ᐔᚑ
㪈䋹ᐕᐲ

䈖䉏䉁䈪ฦ⋭䈪ᢛ஻䈘䉏䈢䊂䊷䉺䊔䊷䉴䈱ᮮᢿ⊛䈭⛔วൻ䉕ⴕ䈇䇮ᚒ䈏࿖䈱䊤䉟䊐䉰䉟䉣䊮䉴ಽ㊁䈱⎇ⓥᚑᨐ䈮⺕䉅䈏ኈᤃ䈮䉝䉪䉶䉴䈚ᵴ↪䈪䈐䇮ᚒ䈏࿖䈱⎇ⓥ㐿⊒ജ䉕ᦝ䈮ᒝൻ䈘䈞䉎ၮ⋚䈫䈚䈩䈱⛔ว䊂䊷䉺䊔䊷䉴䈱ᢛ஻䈱䈅䉍ᣇ䈮䈧䈇䈩ᬌ⸛䈜䉎䇯䊶㑐ଥ⋭ᐡ䈮䈍䈔䉎ᬌ⸛䊶╙䋳ᦼ⑼ቇᛛⴚၮᧄ⸘↹㪉㪀䈱ᚢ⇛㊀ὐ⑼ቇᛛⴚ㪊㪀䇸਎⇇ᦨ㜞᳓Ḱ䈱䊤䉟䊐䉰䉟䉣䊮䉴ၮ⋚ᢛ஻䇹䈫䈚䈩⛔
ว䊂䊷䉺䊔䊷䉴䉕૏⟎䈨䈔䇯䊶ᢥㇱ⑼ቇ⋭䈱⛔ว䊂䊷䉺䊔䊷䉴䊒䊨䉳䉢䉪䊃䈱㐿ᆎ䊶ㄘᨋ᳓↥⋭䈱⛔ว䊂䊷䉺䊔䊷䉴䊒䊨䉳䉢䉪䊃䈱㐿ᆎ

䊶⑼ቇᛛⴚㅪ៤ᣉ╷⟲䈱ᚑᨐ෸䈶੹ᓟ䈱⷗ㅢ䈚䋨ਛ㑆ႎ๔᩺䋩䉕૞ᚑᬌ⸛⚻✲䊶ᶏᄖ䈱䊋䉟䉥䊥䉸䊷䉴੐ᬺ䈱⽿છ⠪䉕᜗⡜䈚䇮⻠Ṷળ䉕ታᣉ䊶 ✚ว⑼ቇᛛⴚળ⼏䈱䊤䉟䊐䉰䉟䉣䊮䉴㪧㪫䈮⛔ว䊂䊷䉺䊔䊷䉴 䉺䉴䉪䊐䉤䊷䉴䉕⸳⟎

䊶⑼ቇᛛⴚㅪ៤ᣉ╷⟲䈱ᦨ⚳ข䉍䉁䈫䉄䋨⚳ੌ䋩䊶 ╙䋱࿁⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ળว㐿௅䋨䌈䋲䋰㪆䋱䋲㪆䋲䋵䋩

ᐔᚑ
䋲䋰ᐕᐲ

䊶✚ว⑼ቇᛛⴚળ⼏䊤䉟䊐䉰䉟䉣䊮䉴㪧㪫䈮䇸⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴䇹䈱⸳⟎ 䋨ᐳ㐳 ੖᪯ၳ ቁ䋩䊶 ⚻ᷣ↥ᬺ⋭䈱⛔ว䊂䊷䉺䊔䊷䉴䊒䊨䉳䉢䉪䊃䈱㐿ᆎ䇯ᐔᚑ䋲䋱ᐕᐲ䊶䇸⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴䇹䈱ႎ๔ᦠ䈱╷ቯ䋨䋴᦬䋱䋰ᣣ䋩ᐔᚑ㪉㪈ᐕᐲ᭎▚ⷐ᳞䈱ఝవ㗅૏ઃ䈔䈮䈍䈇䈩䇮䇸ᢥㇱ⑼ቇ⋭⛔ว䊂䊷䉺䊔䊷䉴䊒䊨䉳䉢䉪䊃䈫㪡㪪㪫䊋䉟䉥䉟䊮䊐䉤䊙䊁䉞䉪䉴ផㅴ䉶䊮䉺䊷䋨㪙㪠㪩㪛䋩䈫䈱৻૕ൻ䉕⋡ᜰ䈚䈩䇮ടㅦ䈚䈩੐ᬺ䉕ታᣉ䈜䉎ᔅⷐ䈏䈅䉎䇯䇹 䈫⹏ଔ䊶 ╙䋲࿁⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ળว㐿௅䋨㪟䋲䋱㪆䋱㪆䋲䋱䋩䊶 ╙䋳࿁⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ળว㐿௅䋨㪟䋲䋱㪆䋲㪆䋱䋷䋩䊶 ╙䋴࿁⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ળว㐿௅䋨㪟䋲䋱㪆䋳㪆䋱䋸䋩1) ⑼ቇᛛⴚㅪ៤ᣉ╷⟲䋺ฦᐭ⋭䈱❑ഀ䉍䈱ᣉ╷䈮ᮮਠ䉕ೝ䈜ข䉍⚵䉂2) ╙䋳ᦼ⑼ቇᛛⴚၮᧄ⸘↹䋺ᐔᚑ䋱䋸ᐕᐲ䈎䉌䋵ᐕ㑆䈱ᚒ䈏࿖䈮䈍䈔䉎⑼ቇᛛⴚ䈱ផㅴᚢ⇛3) ᚢ⇛㊀ὐ⑼ቇᛛⴚ䋺․䈮㊀ⷐ䈭ᛛⴚ䉕ㆬᛯ䈚䇮⎇ⓥ⾗㊄䉕㓸ਛ䈘䈞䉎䈼䈐ಽ㊁

2

᭴ᚑຬ

⿰ᣦ

㑐ଥᐭ⋭䈱ข⚵䉂

䊶⑼ቇᛛⴚㅪ៤ᣉ╷⟲ 䇸↢๮⑼ቇၮ␆䊶ၮ⋚䇹䈱㐿ᆎ 䋨ਥ⋙ ੖᪯ၳ ቁ䋩䊶⵬ቢ⊛⎇ⓥ⺖㗴 䇸↢๮⑼ቇ䊂䊷䉺䊔䊷䉴⛔ว䈮㑐䈜䉎⺞ᩏ⎇ⓥ䇹䈱ታᣉ 䋨⎇ⓥઍ⴫⠪ ᄢਭ଻ ౏╷ 䋩

* EMBL (European Molecular Biology Laboratory):᰷Ꮊ19䈎࿖䈱಴⾗䈮䉋䉍⸳┙䈘䉏䈢ಽሶ↢‛ቇ䈱⎇ⓥᚲ

䊤䉟䊐䉰䉟䉣䊮䉴䌐䌔 ⛔ว䊂䊷䉺䊔䊷䉴 䉺䉴䉪䊐䉤䊷䉴ળว✚ว䊂䊷䉺䊔䊷䉴੐ᬺ䈻䈱ข⚵䉂✚ว⑼ቇᛛⴚળ⼏䈮䈍䈔䉎ข⚵䉂

ᚒ䈏࿖䈮
৻ర⊛䈎䈧
ᕡਭ⊛䈭
䊤䉟䊐䉰䉟䉣䊮䉴䈱⛔ว䊂䊷䉺䊔䊷䉴䈏ᔅⷐ䊶 ╙䋵࿁⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ળว㐿௅䋨䌈䋲䋱㪆䋴㪆䋲䋩

䇼ᐳ㐳䇽
੖᪯ၳ ቁ

䊤䉟䊐䉰䉟䉣䊮䉴䌐䌔೽ᐳ㐳䇮࿖┙ㆮવቇ⎇ⓥᚲ೽ᚲ㐳䊶
ᢎ᝼

䇼᦭⼂⠪䇽
ᵻፉ ⺈
䋨⁛䋩 ↥ᬺᛛⴚ✚ว⎇ⓥᚲ ེቭ⊒↢Ꮏቇ⎇ⓥ䊤䊗㐳ᄢ⍹ ㆏ᄦ䋨⽷䋩 䈎䈝䈘㪛㪥㪘⎇ⓥᚲ ᚲ㐳ዊᐈ ⵨৻䋨⁛䋩 ℂൻቇ⎇ⓥᚲ䊋䉟䉥䊥䉸䊷䉴䉶䊮䉺䊷 䉶䊮䉺䊷㐳ዊጊ ඳผ䋨࿖䋩 ᧲੩ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ ᢎ᝼ൎᧁ ర਽䋨⁛䋩 ᣣᧄቇⴚᝄ⥝ળ ቇⴚ䉲䉴䊁䊛⎇ⓥ䉶䊮䉺䊷 ೽ᚲ㐳ዊේ 㓶ᴦ䋨౒䋩 ᖱႎ䊶䉲䉴䊁䊛⎇ⓥᯏ᭴ ℂ੐᭏ ૫ਯ䋨࿖䋩 ⼾ᯅᛛⴚ⑼ቇᄢቇ ቇ㐳૒䇱ᧁ ථᴦ 䋨⁛䋩 ㄘᬺ↢‛⾗Ḯ⎇ⓥᚲ ℂ੐⺪⸰ ’ሶ䋨⁛䋩 ↥ᬺᛛⴚ✚ว⎇ⓥᚲ ↢๮ᖱႎᎿቇ⎇ⓥ䉶䊮䉺䊷ਥᐙ⎇ⓥຬ
␲ῳᳯ ෹ቁ
࿖┙䈏䉖䉶䊮䉺䊷 䈏䉖ኻ╷ᖱႎ䉶䊮䉺䊷䈏䉖ᖱႎ䊶⛔⸘ ㇱ㐳㜞ᧁ ೑ਭ䋨౒䋩 ᖱႎ䊶䉲䉴䊁䊛⎇ⓥᯏ᭴䊤䉟䊐䉰䉟䉣䊮䉴⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷ᢎ᝼౗䉶䊮䉺䊷㐳⼾↰ ື㇢䋨⁛䋩 ℂൻቇ⎇ⓥᚲ ↢๮ᖱႎၮ⋚⎇ⓥㇱ㐷㐳㐳ᵮ Პᔒ䉣䊷䉱䉟ᩣᑼળ␠ ℂ੐䊶⎇ⓥ㐿⊒ᜂᒰઃ ᜂᒰㇱ㐳ਛ᧛ ᤐᧁ䋨࿖ 䋩ᄢ㒋ᄢቇⰮ⊕⾰⎇ⓥᚲ㒝ዻ䊒䊨䊁䉥䊚䉪䉴✚ว⎇ⓥ䉶䊮䉺䊷 ᢎ᝼䊶䉶䊮䉺䊷㐳Ⴧ੗ ᔀ䋨⁛䋩 ක⮎ၮ⋚⎇ⓥᚲ ↢‛⾗Ḯ⎇ⓥㇱ ㇱ㐳᳓਄ ᡽ਯ䋨⁛䋩 ⑼ቇᛛⴚᝄ⥝ᯏ᭴ ℂ੐ᮮጊ ⨃ਯ䋨⁛䋩 ℂൻቇ⎇ⓥᚲ ↢๮ಽሶ䉲䉴䊁䊛ၮ⋚⎇ⓥ㗔ၞ
㗔ၞ㐳
ศ↰ ノᒾ
࿖┙䈏䉖䉶䊮䉺䊷⎇ⓥᚲ
⣲≌䉭䊉䊛⸃ᨆ䊶ᖱႎ⎇ⓥㇱ ㇱ㐳ᐔᚑ䋲䋰ᐕ䋱䋲᦬䉋䉍䋵࿁㐿௅䇯ᧄᐕ䋴᦬䋱䋰ᣣ䈮⛔ว㪛㪙䉺䉴䉪䊐䉤䊷䉴ႎ๔ᦠ䉕䈫䉍䉁䈫䉄䇯3

㪋

1

ᣂߒ޿⛔ว࠺࡯࠲ࡌ࡯ࠬߩ⚵❱૕೙ ╙৻Ბ㓏㧕⛔ว䊂䊷䉺䊔䊷䉴䈱ਛᩭᯏ㑐䈱ᔅⷐᕈ䇼⛔ว䊂䊷䉺䊔䊷䉴ផㅴᧄㇱ䋨઒⒓䋩䈱⸳⟎䇽䊶 䇸⛔ว䊂䊷䉺䊔䊷䉴ផㅴᧄㇱ䋨઒⒓䋩䇹䈲䉥䊷䊦䉳䊞䊌䊮䈱ⷞὐ䈪䇮⛔ว䊂䊷䉺䊔䊷䉴䈱ㆇ༡䈮㑐䈜䉎ม઎Ⴁ䈫䈚䈩ᯏ⢻䇯䊶 ✚ว⑼ቇᛛⴚળ⼏䈱䊤䉟䊐䉰䉟䉣䊮䉴PT䈮㒝ዻ䈚䈩⸳⟎䇯䇼⛔ว䊂䊷䉺䊔䊷䉴⹏ଔᆔຬળ䋨઒⒓䋩䈱⸳⟎䇽䊶䇸⛔ว䊂䊷䉺䊔䊷䉴⹏ଔᆔຬળ䋨઒⒓䋩䇹䈲䇸⛔ว䊂䊷䉺䊔䊷䉴 䉶䊮䉺䊷䋨઒⒓䋩䇹䈱ㆇ༡ో⥸䈮䈧䈇䈩⹏ଔ䈜䉎ᯏ⢻䇯䊶 䇸⛔ว䊂䊷䉺䊔䊷䉴ផㅴᧄㇱ䋨઒⒓䋩䇹䈱⻁໧ᯏ㑐䈫䈚䈩⸳⟎䇯䇼⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨઒⒓䋩䈱⸳⟎䇽䊶 䇸⛔ว䊂䊷䉺䊔䊷䉴 䉶䊮䉺䊷䋨઒⒓䋩䇹䈲䇮䉶䊮䉺䊷㐳䈱䊥䊷䉻䊷䉲䉾䊒䈱ਅ䇮䊂䊷䉺䊔䊷䉴⛔ว䈮ᔅⷐ䈭⺞ᩏ䇮ᮡḰൻ䇮䉲䉴䊁䊛䈱᭴▽䊶⛽ᜬ䊶▤ℂ䇮䊘䊷䉺䊦䉰䉟䊃᭴▽䇮DB䈱ฃ౉䉏䊶▤ℂ䊶ᦝᣂ䇮䊂䊷䉺䊔䊷䉴䈱ຠ⾰▤ℂ╬䈱ᬺോ䉕ታᣉ䈜䉎ᯏ⢻䇯䊶ᄢቇ౒ห೑↪ᯏ㑐ᴺੱ ᖱႎ䊶䉲䉴䊁䊛⎇ⓥᯏ᭴䋨䌒䌏䌉䌓䋩䈮⸳⟎䈚䈢䊤䉟䊐䉰䉟䉣䊮䉴⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䉕ਛᔃ䈮ታᣉ䈚䈩䈐䈢ᢥㇱ⑼ቇ⋭⛔วDB䊒䊨䉳䉢䉪䊃䈫⁛┙ⴕ᡽ᴺੱ ⑼ቇᛛⴚᝄ⥝ᯏ᭴䋨JST䋩䈱䊋䉟䉥䉟䊮䊐䉤䊙䊁䉞䉪䉴ផㅴ䉶䊮䉺䊷੐ᬺ䈫䉕৻ᧄൻ䈚䇮 䌊䌓䌔䈱ᣂ䈢䈭⚵❱䈫䈚䈩ᢛ஻䇯䇼⛔ว䊂䊷䉺䊔䊷䉴ㆇ༡ᆔຬળ䋨઒⒓䋩䈱⸳⟎䇽䊶䇸⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨઒⒓䋩䇹䈱ౕ૕⊛䈭੐ᬺ䈮㑐䈜䉎ද⼏䊶⺞ᢛ䈱ᯏ⢻䇯䊶䇸⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨઒⒓䋩䇹䈮⸳⟎䇯䇼࿖ౝ䈱DB䈱ᵴ↪䈫లታ䊶ᒝൻ䇽䈖䉏䉁䈪㑐ଥ⋭ᐡ䇮⎇ⓥᯏ㑐䋨੐ᬺ䋩䇮ડᬺ╬䈪ข䉍⚵䉁䉏䈩䈐䈢DB䋨ᣢሽ䈱ฦ⋭䈱⛔วDB䉕฽䉃䋩䈮䈧䈇䈩䉅ᒁ䈐⛯䈐ㆡಾ䈭ᢛ஻䉕࿑䉎䇯䇼ၮᧄ⹺⼂䇽
ᚒ䈏࿖䈱⎇ⓥ㐿⊒ၮ⋚䈱ᦝ䈭䉎ᒝൻ䈱䈢䉄䇮⎇ⓥ䈱ᚑᨐ䈫䈚䈩↥಴䈘䉏䈢ᄙ᭽䈭䊂䊷䉺䉕೑↪⠪䈱ⷞὐ䈮┙䈦䈩⛔วൻ䈚䇮ല₸䉋䈒⎇ⓥ⠪䇮↥ᬺ⇇䇮䈘䉌䈮䈲࿖᳃䈮ㆶర䈚䈩䈇䈒䇮৻ర⊛䈎䈧ᕡᏱ⊛䈭䊤䉟䊐䉰䉟䉣䊮䉴䈱⛔ว䊂䊷䉺䊔䊷䉴䈱᭴▽䈏ᔅⷐ䈪䈅䉍䇮䈠䈱䈢䉄䈱ਛᩭᯏ㑐䈏ਇนᰳ䇼᳞䉄䉌䉏䉎ᯏ⢻䇽䂾ฦ⋭╬䈮䈍䈔䉎䊂䊷䉺䊔䊷䉴䉅฽䉄䇮ᚒ䈏࿖ో૕䈮ᢔ࿷䈜䉎䊂䊷䉺䊔䊷䉴䉕᦭ല䈮૶䈉䈖䈫䈱䈪䈐䉎ㆇ↪䉕⋡ᜰ䈚䈢৻ర⊛䈭䊈䉾䊃䊪䊷䉪ൻ䈱᭴▽䊂䊷䉺䊔䊷䉴⛔ว䈮ᔅⷐ䈭⺞ᩏ䇮䊂䊷䉺䊔䊷䉴䈱⛔ว䈮ᔅⷐ䈭ᮡḰൻ䇮䉲䉴䊁䊛䈱᭴▽䊶⛽ᜬ䊶▤ℂ䇮䊘䊷䉺䊦䉰䉟䊃䈱᭴▽䇮䊂䊷䉺䊔䊷䉴䈱ฃ౉䉏䊶▤ℂ䊶ᦝᣂ䇮䊂䊷䉺䊔䊷䉴䈱ຠ⾰▤ℂ䇮ฦ⋭╬䈱䊂䊷䉺䊔䊷䉴䈫䈱䊈䉾䊃䊪䊷䉪䈱᭴▽䇮ᶏᄖ䈫䈱ㅪ៤╬䈱ታോᯏ⢻䈮ട䈋䈩䇮䊂䊷䉺䊔䊷䉴䈱⛔วൻ䉇㜞ᐲ䈭ᬌ⚝╬䇮⛔ว⊛೑↪䈱䈢䉄䈱ᛛⴚ㐿⊒䋨䉟䊮䊂䉾䉪䉴䇮ㄉᦠ䇮䊂䊷䉺䊐䉤䊷䊙䉾䊃䈭䈬䈱᭴▽䋩䈱ᯏ⢻

䂾࿖㓙ㅪ៤

CSTP

᰷☨⻉࿖䈱䉂䈭䉌䈝䇮੹ᓟ䈱⊒ዷ䈏੍᷹䈘䉏䉎䉝䉳䉝⻉࿖䈫䉅ኒធ䈭ㅪ៤䉕ផㅴ⛔ว䊂䊷䉺䊔䊷䉴ផㅴᧄㇱ(઒⒓䋩䊤䉟䊐䉰䉟䉣䊮䉴䌐䌔䂾ੱ᧚⢒ᚑ⛔ว䊂䊷䉺䊔䊷䉴⹏ଔᆔຬળ䋨઒⒓䋩㜞ᐲ䈭ኾ㐷ᕈ䉕஻䈋䈢ੱ᧚䈱⛮⛯⊛䈭⢒ᚑ䉇䇮ᄢቇ╬䈫䉅ㅪ៤䈚䈢䉨䊞䊥䉝䊌䉴䈱᭴▽⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨઒⒓䋩䉶䊮䉺䊷㐳JST

䇼ᬌ⸛੐㗄䇽
䂾ㆇ༡⾌䈱⏕଻䇼⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䇽⛔ว䊂䊷䉺䊔䊷䉴ㆇ༡ᆔຬળ䋨઒⒓䋩

⛔ว䊂䊷䉺䊔䊷䉴ᢛ஻䊶⛔วታᣉ⠪䋺䋨䊤䉟䊐䉰䉟䉣䊮䉴⎇ⓥ⠪䇮䊋䉟䉥䉟䊮䊐䉤䊙䊁䉞䉪䉴ᛛⴚ⠪䇮DB㐿⊒⠪╬䋩䉥䊷䊦䉳䊞䊌䊮䈱૕೙䈮⋧ᔕ䈚䈇ᣂ䈢䈭ᡰេ䈱઀⚵䉂䈱ᬌ⸛㶎 ⛔วDB䊒䊨䉳䉢䉪䊃䈱䊥䉸䊷䉴䉕㓸⚂䇮⛮ᛚ䂾䊂䊷䉺⊓㍳䈱ផㅴ䋨䉟䊮䉶䊮䊁䉞䊑䈱⏕଻䋩DBs⛔ว䊂䊷䉺䊔䊷䉴䈻䈱䊂䊷䉺⊓㍳䈏ㅴ䉃䉋䈉䇮⊓㍳⁁ᴫ䉕⹏ଔ䈜䉎઀⚵䉂䈱ᬌ⸛䂾ੱ૕䈮↱᧪䈜䉎䊂䊷䉺╬䈱ข䉍ᛒ䈇DBੱ૕䈮↱᧪䈜䉎䊂䊷䉺╬䈮䈧䈇䈩䈲䇮෼㓸╬䈮ᘕ㊀䈭ኻᔕ䈏ᔅⷐ䈪䈅䉍䇮䈠䈱ᣇ㊎䉕ᬌ⸛

5

DB

DBs
DB

DB

DBs
DB

DB

DB
DB
DB
DB
DB
DB
ၮ⋚⊛
ᄢቇ䊶౏⊛ᯏ㑐ડᬺ╬࿖䇮⁛ᴺ╬䈮䉋䉎౏⊛⾗㊄

DB
DB
䈠䈱ઁ୘೎

࿖ౝ䈱䊂䊷䉺䊔䊷䉴䈱ᵴ↪䈫లታ䇮ᒝൻ㪍⛔ว䊂䊷䉺䊔䊷䉴ᢛ஻䈱䊨䊷䊄䊙䉾䊒
╙৻Ბ㓏

Ḱ஻Ბ㓏

⃻࿷

ᐔᚑ䋲䋲ᐕᐲ

ᐔᚑ䋲䋰ᐕᐲ
⛔วDB
䉺䉴䉪
䊐䉤䊷䉴

CSTP

ㅴ
᝞ഥ
⏕⸒
⹺丵

╙ੑᲑ㓏

䋵ᐕᓟ
ᐔᚑ䋲䋵ᐕᐲ

⛔ว䊂䊷䉺䊔䊷䉴ផㅴᧄㇱ䋨઒⒓䋩
⛔ว䌄䌂䈱ᕡਭൻ䈱䈅䉍ᣇ䈱ᬌ⸛• ⛔วDB䉶䊮䉺䊷䈱⸳⟎䈮ะ䈔䈢ㅴ᝞▤ℂ• ㆇ༡⚻⾌䈮䈧䈇䈩ᬌ⸛ౕ૕⊛䈭ታᣉ䈮ะ䈔䈢ഥ⸒╬㵶 ⛔ว㪛㪙䉶䊮䉺䊷䈱䈅䉍ᣇ䈱ᬌ⸛ᐔᚑ23ᐕ
㵶 ⛔ว㪛㪙䉶䊮䉺䊷䈱ㆇ༡䈮䈧䈇䈩䈱ᜰዉ䊶ഥ⸒
4᦬1ᣣ

ᬌ⸛䈱
ข䉍䉁䈫䉄

৻૕ൻ
ᢥㇱ⑼ቇ⋭
⛔ว䊂䊷䉺䊔䊷䉴䊒䊨䉳䉢䉪䊃JST 䊶 BIRDฦ⋭╬䈱䊂䊷䉺䊔䊷䉴

⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨઒⒓䋩䋨╙৻Ბ㓏䋩
JST

DB⛔วDB䊒䊨䉳䉢䉪䊃⛔วDB䊒䊨䉳䉢䉪䊃

DB⛔วDB䊒䊨䉳䉢䉪䊃⛔วDB䊒䊨䉳䉢䉪䊃

DB
୘೎ᯏ㑐䈱
䊂䊷䉺䊔䊷䉴

DB
DB

DB

ᣂ䈢䈭
⛔ว䊂䊷䉺䊔䊷䉴䉶䊮䉺䊷䋨╙ੑᲑ㓏䋩

ḩ䈢䈜䈼䈐ᔅⷐ᧦ઙ
(1) ⛮⛯ᕈ(2) ᖱႎ䈱ഃ಴䈫೑↪䈱෺ᣇ䈱ᗧ⷗䉕෻ᤋ䈪䈐䉎ㆇ༡(3) ታ㓙䈱ᬺോ╬䉕ㅢ䈚䈩䈱ੱ⽷⢒ᚑᯏ⢻(4) 㑐ଥ⋭ᐡ䈱ᡰេ㪎

2

⑼ቇ䈱ᕈ⾰㪉㪇㪇㪐ᐕ㪋᦬㪉㪈ᣣ䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛⑼ቇ䈱ᜬ䈧㪉䈧䈱ᕈ⾰䃂ੱ䈮ᄺ઀䈜䉎㘺䈇䈭䉌䈘䉏䈢ᖱႎʴầᅹ‫ܖ‬ᄂᆮỉ‫ݣ‬ᝋểễỦẮểểỊᾎἪἽἉὅỿܳᚕỉોᚖ཯ᇌᘍ૎ඥʴҔᕤؕႴᄂᆮ৑

䃂㘺䈇䈭䉌䈜䈖䈫䈱䈪䈐䈭䈇ರ᥸ᕈ䉕ᜬ䈧ᵴേ䈫䈚䈩䈱⑼ቇ
ರ᥸ᕈ䉕ᜬ䈧
ᧂ᧪䈮ዻ䈜䉎ᵴേ䊷⚂᧤䈪䈲䈭䈇䇯੍ᗐ䈱▸࿐䉕⿥䈋䉎ᵴേ䈫䈚䈩䈱⑼ቇ

‫ف‬ʟ࣋

2

⚵❱䊶⚦⢩䈫ᖱႎ䈱౒᦭ൻ
↱᧪⠪

ක⠪

↱᧪⠪

ක⠪

↱᧪⠪

ක⠪

↱᧪⠪
↱᧪⠪
↱᧪⠪

䊓䊦䉲䊮䉨ት⸒䈱ᄌㆫ

⎇ⓥ⠪
⎇ⓥ⠪
⎇ⓥ⠪

዁᧪䈱
ක≮䈱႐
කᏧ

ડᬺ

⎇ⓥ⾗Ḯ
䊋䊮䉪
⚦⢩䊶⚵❱
ᖱႎ

ડᬺ
ડᬺ

዁᧪䈱
ᖚ⠪䊶Ꮢ᳃
3

1964: “Clinical research on a human being”
being”
I. Introduction
II. Clinical research combined with professional care
III. Non-therapeutic clinical research
1975: “Biomedical research involving human subjects”
subjects”
Introduction
I. Basic principles
II. Medical research with professional care. (Clinical research)
III. Non-therapeutic biomedical research involving humansubjects. (Non-clinical biomedical research
2000:
2000 “Medical research involving human subjects.
subjects.”
A. Introduction
B. Basic principles for all medical research
C. Additional principles for medical research combinedwith medical care
41

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋱䋩䋱䋮䊶䊶䊶The Declaration is intended to be readas a whole and each of its constituent
paragraphs should not be applied without
consideration of all other relevant
paragraphs.
䋱䋮䊶䊶䊶ᧄት⸒䈲䇮✚ว⊛䈮⸃㉼䈘䉏䉎䈖䈫䉕ᗧ࿑䈚䈢䉅䈱䈪䈅䉍䇮ฦ㗄⋡䈲ઁ䈱䈜䈼䈩䈱㑐ㅪ㗄⋡䉕⠨ᘦ䈮౉䉏䈝ㆡᔕ䈘䉏䉎䈼䈐䈪䈲䈭䈇䇯

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋳䋩
䋱䋹䋮Every clinical trial must be registered in a
publicly accessible database before recruitmentof the first subject.
䋱䋹䋮䈜䈼䈩䈱⥃ᐥ⹜㛎䈲䇮ᦨೋ䈱ⵍ㛎⠪䉕൐㓸䈜䉎೨䈮䇮৻⥸⊛䈮䉝䉪䉶䉴น⢻䈭䊂䊷䉺䊔䊷䉴䈮⊓㍳
䈘䉏䈭䈔䉏䈳䈭䉌䈭䈇䇯

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋲䋩
䋶䋮In medical research involving human subjects, thewell-being of the individual research subject must takeprecedence over all other interests.
䋶䋮ੱ㑆䉕ኻ⽎䈫䈜䉎කቇ⎇ⓥ䈮䈍䈇䈩䈲䇮୘䇱䈱⎇ⓥⵍ㛎⠪䈱⑔␩䈏ઁ䈱䈜䈼䈩䈱೑⋉䉋䉍䉅ఝవ䈘䉏䈭䈔䉏䈳䈭䉌
䈭䈇䇯
2000ᐕ
䋵䋮In medical research involving human subjects, thewell-being of the individual research subject should takeprecedence over all other interests.
䋵䋮䊍䊃䉕ኻ⽎䈫䈜䉎කቇ⎇ⓥ䈮䈍䈇䈩䈲䇮ⵍ㛎⠪䈱⑔೑䈮ኻ䈜䉎㈩ᘦ䈏⑼ቇ⊛䈍䉋䈶␠ળ⊛೑⋉䉋䉍䉅ఝవ䈘䉏䈭䈔䉏䈳䈭䉌䈭䈇䇯

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋴䋩䋲䋵䋮For medical research using identifiable humanmaterial or data, physicians must normally seek consent
for the collection, analysis, storage and/or reuse. Theremay be situations where consent would be impossible or
impractical to obtain for such research or would pose athreat to the validity of the research.
research In such situations
the research may be done only after consideration andapproval of a research ethics committee.
䋲䋵䋮୘ੱ䉕․ቯ䈚䈉䉎䊍䊃↱᧪䈱⹜ᢱ䉁䈢䈲䊂䊷䉺䉕૶↪䈜䉎කቇ⎇ⓥ䈮㑐䈚䈩䈲䇮කᏧ䈲෼㓸䇮ಽᨆ䇮଻ሽ䈍䉋䈶䋯䉁䈢䈲ౣ೑↪䈮ኻ䈜䉎หᗧ䉕ㅢᏱ᳞䉄䈭䈔䉏䈳䈭䉌䈭䈇䇯䈖䈱䉋䈉䈭⎇ⓥ䈮䈲䇮หᗧ䉕ᓧ䉎䈖䈫䈏ਇน⢻䈪䈅䉎䈎㕖⃻ታ⊛หᗧ䉕ᓧ䉎䈖䈫䈏ਇน⢻䈪䈅䉎䈎㕖⃻ታ⊛䈪䈅䉎႐ว䇮䉁䈢䈲⎇ⓥ䈱᦭ലᕈ䈮⢿ᆭ䉕ਈ䈋䉎႐ว䈏䈅䉍ᓧ䉎䇯䈖䈱䉋䈉䈭⁁ᴫਅ䈱⎇ⓥ䈲䇮⎇ⓥ୶ℂᆔຬળ䈱ክ⼏䉍ᓧ䉎䈫ᛚ⹺䉕ᓧ䈢ᓟ䈮䈱䉂ⴕ䈉䈖䈫䈏䈪䈐䉎䇯2

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋵䋩

2008ᐕ䊓䊦䉲䊮䉨ት⸒ᡷ⸓䋨䋵䋩䋳䋰䋮䊶䊶䊶Negative and inconclusive as well as
positive results should be published or otherwise
made publicly available.

䋲䋹䋮䊶䊶If no such representative is available and if theresearch cannot be delayed,delayed the study may proceedwithout informed consent provided that the specificreasons for involving subjects with a condition that
renders them unable to give informed consent havebeen stated in the research protocol and the study has
been approved by a research ethics committee.
䋲䋹䋮䊶䊶䈖䈱䉋䈉䈭⁁ᴫ䈪䈲䇮කᏧ䈲ᴺᓞ਄䈱ᮭ㒢䉕᦭䈜䉎ઍ
ℂੱ䈎䉌䈱䉟䊮䊐䉤䊷䊛䊄䊶䉮䊮䉶䊮䊃䉕᳞䉄䉎䈼䈐䈪䈅䉎䇯䈠䈱䉋䈉䈭ઍℂੱ䈏ሽ࿷䈞䈝䇮䈎䈧⎇ⓥ䉕ᑧᦼ䈜䉎䈖䈫䈏䈎䈧⎇ⓥ䉕ᑧᦼ䈜䉎䈖䈫䈏䈪䈐䈭䈇႐ว䈮䈲䇮䉟䊮䊐䉤䊷䊛䊄䊶䉮䊮䉶䊮䊃䉕ਈ䈋䉎䈖䈫䈏䈪䈐䈭䈇႐ว
䈪䈐䈭䈇⁁ᘒ䈮䈅䉎ⵍ㛎⠪䉕ኻ⽎䈫䈜䉎․೎䈭ℂ↱䉕⎇ⓥ⸘↹ᦠ䈱ਛ䈪ㅀ䈼䇮䈎䈧⎇ⓥ୶ℂᆔຬળ䈪ᛚ⹺䈘䉏䉎䈖䈫䉕᧦ઙ䈫䈚䈩䇮䈖䈱⎇ⓥ䈲䉟䊮䊐䉤䊷䊛䊄䊶䉮䊮䉶䊮䊃䈭䈚䈮㐿ᆎ䈜䉎䈖䈫䈏䈪䈐䉎䇯䋳䋰䋮䊶䊶䊶ᶖᭂ⊛⚿ᨐ䈍䉋䈶⚿⺰䈮㆐䈚䈭䈇⚿ᨐ⚿⺰䈮㆐䈚䈭䈇⚿ᨐ䉅Ⓧᭂ⊛⚿ᨐ䈫ห᭽䈮䇮౏ೀ䉁䈢䈲ઁ䈱ᣇᴺ䈪৻⥸䈮౏⴫䈘䉏䉎䈼䈐䈪䈅䉎䇯ೀⴕ‛䈱ਛ䈮䈲䇮⾗㊄Ḯ䇮⚵❱䈫䈱㑐䉒䉍䈍䉋䈶೑⋉⋧෻䈏᣿␜䈘䉏䉎ᔅⷐ䈏䈅䉎 䇯3䇸䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛䈱䈖䉏䉁䈪䇹㩷㩷╙䋱࿁䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛㩷䊁䊷䊙䋺䇸䉝䉳䉝䈪䈏䉖ᖱႎ䉕㓸䉄䉎䈖䈫䈱ᗧ๧䈫䈲䈭䈮䈎䇹㩷ᣣᤨ䋺ᐔᚑ䋲䋰ᐕ䋶᦬䋶ᣣ䋨㊄䋩㩷ඦᓟ䋳ᤨ䋳䋰ಽ䌾㩷႐ᚲ䋺ෘ↢ഭ௛⋭㩷 䋷㓏㩷 㪎㪈㪉 ภቶ㩷⹤㗴ឭଏ㩷⿒ᐳ⧷ਯ䋨╳ᵄᄢቇᢎ᝼䋩㩷䉝䉳䉝䈱㵰≸䈱․ᱶᕈ㵱䉕ᛠី䇮෸䈶䉝䉳䉝䈱䉂䈭䉌䈝⷏᰷䈱≸ᴦ≮䈱ᐩ਄䈕䈮ነਈ䈜䉎䈢䉄䈱ᣇ╷䈮䈧䈇䈩㩷ጤፒ㩷 ↭䋨䉫䊤䉪䉸䊶䉴䊚䉴䉪䊤䉟䊮ข✦ᓎ䋩㩷䈏䉖ᴦ≮䈮䈍䈔䉎ᣣᧄ䊶ਛ࿖䊶䉝䉳䉝⻉࿖䈱ක≮䊶කቇ⊛䊂䊷䉺䈱ᢛ஻䈱ᔅⷐᕈ㩷䊙䊦䉮䊛䊶䊛䊷䉝䋨㪬㪠㪚㪚㪄㪘㪩㪦㩷 䋩㩷㪘㫊㫀㪸㫅㩷㪧㪸㪺㫀㪽㫀㪺㩷㪦㫉㪾㪸㫅㫀㫑㪸㫋㫀㫆㫅㩷㪽㫆㫉㩷㪚㪸㫅㪺㪼㫉㩷㪧㫉㪼㫍㪼㫅㫋㫀㫆㫅㩷㪸㫅㪻㩷㪚㫆㫅㫋㫉㫆㫃㩷㩷╙ 㪉 ࿁㩷 䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛㩷䊁䊷䊙䋺䇸䉝䉳䉝䈏䉖ක≮ㅪ៤䈮䈍䈔䉎࿖⋉䈱ਛᔃ䈲䈬䈖䈭䈱䈎䋿䇹㩷ᣣᤨ䋺ᐔᚑ 㪉㪇 ᐕ㩷 㪈㪉 ᦬ 㪏 ᣣ㩷 䋨᦬䋩㩷 㩷ඦᓟ 㪉 ᤨ㵪ඦᓟ 㪌 ᤨ 㪊㪇 ಽ㩷႐ᚲ䋺ㇺ㆏ᐭ⋵ળ㙚㩷 㪋㪈㪇㩷 㩷㩷⹤㗴ឭଏ㩷╙ 㪈 ㇱ㩷 㩷 䉝䉳䉝䈏䉖䉕䉄䈓䉎੹ᣣ⊛⁁ᴫ㩷 㩷 㩷 㩷 㩷 㩷 㩷䋱䉝䉳䉝䈏䉖ㅴ᝞⁁ᴫ㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 ෘ↢ഭ௛⋭೨↰శ຦䈏䉖ኻ╷ផㅴቶ㐳㩷 㩷ᣣਛ㖧ਃ࿖ෘ↢ᄢ⤿ળว䋨㪈㪈 ᦬ 㪉 ᣣ䋩䈱วᗧ੐㗄䈱⺑᣿㩷 㩷 㩷 㩷 㩷䋲䌁䌐䌆䌏䌃䌃䈫䌁䌐䌃䌃㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 ᗲ⍮䈏䉖䉶䊮䉺䊷ᚲ㐳㩷 ↰ፉ๺㓶㩷 㩷䋳㩷 㪉㪇㪇㪐 ᐕ㩷 䉝䉳䉝ᄥᐔᵗ䈏䉖ቇળ㩷 㐿௅䈮䈧䈇䈩㩷 㩷 ╳ᵄᄢቇᢎ᝼㩷 㩷 ⿒ᐳ⧷ਯ㩷 㩷 㩷䋴㩷 䉝䉳䉝ක≮ㅪ៤䈫ᣣᧄ䈱↥ᬺ᭴ㅧ㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 ᧲੩ᄢቇᢎ᝼㩷 㩷 㩷 ਃቛᷕ㩷 㩷㩷╙ 㪉 ㇱ㩷 㩷 䇸䉝䉳䉝䈮䈍䈔䉎䈏䉖ක≮ㅪ៤䈮䈍䈇䈩䇮ᣣᧄ䈱࿖⋉䈱ਛᔃ䈲䈬䈖䈭䈱䈎䇹㩷 㩷 㩷
䇸⑼ቇᛛⴚᄖ੤䈫࿖⋉䈮䈧䈇䈩䇹㩷ౝ㑑ᐭෳ੐ቭ䋨䊤䉟䊐䉰䉟䉣䊮䉴ᜂᒰ䋩㩷㊀☍๺ᒄ㩷䇸࿖⋉䈫ᄖ੤䇹㩷 㩷ᄖോ⋭㩷 䉝䉳䉝ᄢᵗᎺዪෳ੐ቭ㩷 ዊේ㓷ඳ㩷㩷㩷㩷╙ 㪊 ࿁㩷 䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛㩷 㩷 㩷㩷ᣣᤨ䋺ᐔᚑ 㪉㪈 ᐕ㩷 㪉 ᦬ 㪎 ᣣ㩷 㩷 ඦᓟ 㪉 ᤨ㵪ඦᓟ 㪌 ᤨ㩷႐ᚲ䋺࿖ㅪᄢቇ䉣䊥䉱䊔䉴䊖䊷䊦㩷 㩷 ౒௅㩷 㪪㪺㫀㪛㪼㫍㪅㪥㪼㫋㩷㩷䇸ᄙᭂൻ䈜䉎਎⇇䈱䈭䈎䈪㩷 㩷㩷 㩷 㩷 䉝䉳䉝䈮ะ䈔䈩㩷 ੹૗䉕䈭䈜䈼䈐䈎㩷 䋭㩷 ࿖㓙ක≮ㅪ៤䈱ᨐ䈢䈜ᓎഀ䇹㩷
㩷
⹤㗴ឭଏ㩷
㩷
╙ 㪈 ㇱ㩷 㩷 㩷 䉝䉳䉝䈏䉖䉕䉄䈓䉎੹ᣣ⊛⁁ᴫ㩷 㩷 㩷 㩷 㩷 㩷 㩷㩷 䋱㩷 ∔∛᭴ㅧ䈱ᄌൻ䈫࿖ㅪ䇸䊚䊧䊆䉝䊛㐿⊒⋡ᮡ䇹䈱ዷᦸ㩷 㩷 㩷 㩷㩷 㩷 㩷 ෘ↢ഭ௛⋭࿖㓙⺖ቶ㐳㩷 ੗਄⡸㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷㩷 䋲㩷 䌕䌉䌃䌃䈫਎⇇ኻ䈏䉖ት⸒㩷 㩷 䌕䌉䌃䌃ᣣᧄᆔຬળᆔຬ㐳㩷 㩷 㩷 㩷 㩷 㩷 ർᎹ⍮ⴕ㩷㩷 䋳㩷 䌁䌐䌃䌃䈱ᓎഀ㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 ╳ᵄᄢቇᢎ᝼㩷 㩷 㩷 㩷 㩷 ⿒ᐳ⧷ਯ㩷 㩷 㩷㩷㩷╙ 㪉 ㇱ㩷
⑼ቇ䉳䊞䊷䊅䊥䉵䊛䈱ᨐ䈢䈜䈼䈐ᓎഀ㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㪛㪸㫍㫀㪻㩷㪛㫀㪺㫂㫊㫆㫅㩷ᄙᭂൻ䈜䉎਎⇇䈱䈭䈎䈪੹਎⇇䈲㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㩷 㤥Ꮉᷡ㩷㩷㩷䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛㩷 䈫䈲㩷㩷䇸䈭䈟䊐䉤䊷䊤䊛䈭䈱䈎䇹㩷䉝䉳䉝⻉࿖䈱⁁ᴫ䈲ᕆᄌ䈚䈩䈍䉍䇮ᚒ䈏࿖䈱੕ᕺ⊛ᚢ⇛੐ᬺ䈮ኻᔕ䈜䉎䈢䉄䈮䈲䇮ᒰೋឝ䈕䈢ᚑᨐ䈫䈲⇣䈭䉎ᚑᨐ䈪䉅⁁ᴫ䈮䉋䈦䈩೨ะ䈐䈮⹏ଔ䈚䇮ㄭ䈇዁᧪䈮ᵴ䈎䈚䈩䈇䈒᡽╷ឭ⸒䉕↥䉂಴䈜⎇ⓥ䈫䈚䈩⢒䈩䈩䈇䈎䈭䈔䉏䈳䇮⎇ⓥ䈱ታᣉ䈲࿎㔍䈪࿖⋉䈫䈚䈩䈱᦭ലᕈ䉅ૐਅ䈜䉎䇯㩷৻⥸䈮䇮⎇ⓥ੐ᬺ䈱ㆬቯ⺖㗴䇮䈍䉋䈶⹏ଔᆔຬળ䈱್ᢿၮḰ䈲᣿⏕䈭䊂䊷䉺䈱಴䉎⎇ⓥ䈮ਥ⌒䉕⟎䈇䈩䈍䉍䇮᡽╷⊛ᐢ䈏䉍䉕ᜬ䈧ឭ⸒䉇ᐢ▸䈪⊛䈱⛉䉎䈖䈫䈱㔍䈚䈇ᥓᘢ䈱⚿㓸䉕ᦼᓙ䈜䉎䈖䈫䈲ኈᤃ䈪䈭䈇䇯䉁䈢䇮࿖ౝ䈱⎇ⓥ⠪䈲䈠䉏䈡䉏䈱ಽ㊁䈱⁛┙䈚䈢ኾ㐷ኅ䈱ነ䉍ว䈇ᚲᏪ䈱஥㕙䉅䈅䉍䇮ో૕䈪䈱ㅪ៤䈏ಽᢿ䈘䉏䈩䈍䉍䇮ᣛ⦘䈫䈭䉎ੱ᧚䈱ㆬቯ䈏㕖Ᏹ䈮㔍䈚䈇㗔ၞ䈪䉅䈅䉎䇯㩷ෳട⠪䈲ක≮䊶⎇ⓥ䊶↥ᬺ䋨ක⮎ຠ㐿⊒䋩䈱౞Ⅳ䉕ୄ⍑䈚䈩䇮ක≮䇮䉝䉦䊂䊚䉝䇮ቭᐡ䇮↥ᬺ⇇䇮䉳䊞䊷䊅䊥䉵䊛䈭䈬䈖䈱໧㗴䉕᭽䇱䈭ⷺᐲ䈎䉌䉂䉎䈖䈫䈏䈪䈐䇮䈭䈍䈎䈧䈠䉏䈡䉏䈱┙႐䈪㊀䈇⽿ോ䉕ᜂ䈦䈩䈇䉎ੱ䉕ੱㆬ䈱䊘䉟䊮䊃䈫䈚䈩䈇䉎䇯వ㍈䈭࿖⋉䈎䉌〒㔌䉕⟎䈐䈭䈏䉌䉅䇮䇸࿖㓙ක≮ㅪ៤䈮䈍䈔䉎዁᧪䈅䉎䈼䈐␠ળ⾗ᧄ䈱ᛩ⾗䈫ᖱႎ᭴▽䇹䈱䈢䉄䈱᦭ᯏ⊛ㅪ៤䉕࿑䉎䉋䈉䈭⎇ⓥᲣ૕䉕᦭䈜䉎ᗧ⟵䈲䈅䉎䈫⠨䈋䉎䇯ᣣᧄ䈱䉝䉳䉝ක≮ㅪ៤䈮䈍䈇䈩䇮ᧄ੐ᬺ䈱䉋䈉䈭ᐢၞ䊐䉤䊷䊤䊛䈱ᨐ䈢䈜ᓎഀ䈲䇮䈖䉏䈎䉌䈘䉌䈮ᄢ䈐䈇䈫ା䈛䉎䇯㩷㩷䇸ᣇะᕈ䇹㩷
䊐䉤䊷䊤䊛䈲䇮⑼ቇ⎇ⓥ䈏䉝䉳䉝࿾ၞ䈪⎇ⓥ䈜䉎ਥ㗴䈫䈚䈩૗䈏น⢻䈪䈅䉍䇮૗䈏⍴ᦼ⊛䈮᦭↪䈪䈅䉍䇮㐳ᦼ⊛䈮䈲૗䈏䈭䈘䉏䉎น⢻ᕈ䈏䈅䉎䈎䈮䈧䈇䈩䇮䈏䉖䈱⥃ᐥᖱႎ䈫∉ቇᖱႎ䈫䈇䈉ゲ䉕ਛᔃ䈫䈲䈚䈧䈧䇮ᐢ䈇▸࿐䈪䈱តᩏᵴേ䉕ⴕ䈉䈖䈫䈪䇮䊐䉤䊷䊤䊛䉕ㅢ䈛䈩౒᦭䈘䉏䉎ᖱႎ䉕ㅢ䈛䈩ᐞ䈧䈎䈱ᣇะᕈ䉕⷗䈧䈔䉋䈉䈫䈜䉎䉅䈱䈪䈅䉎䇯㩷ᧄ᧪䈱⑼ቇ⎇ⓥ䈲䇮䉋䉍⛉䈦䈢ౕ૕⊛䈭ਥ㗴䉕䊘䊥䉲䊠䈚䇮ቢᚑᐲ䈱㜞䈇䉅䈱䈮䈜䉎䈖䈫䈏᳞䉄䉌䉏䉎䈪䈅䉐䈉䈏䇮ᮡḰൻ䈏㔍䈚䈒䇮䇸䈗䉂䊂䊷䉺䇹䈫䉅Ꮛ䈪ៃឦ䈘䉏䉎䈖䈫䈱ᄙ䈇䇮䉝䉳䉝䈫䈇䈉႐䈪૗䈏䈪䈐䉎䈱䈎䇯ᕁ䈇䈧䈐䈪䈭䈇䇮䈚䈎䈚⁛ഃ⊛䈭ᵴേ䉕ᐢ䈕䈩䈇䈒䈢䉄䈮䈲䇮ᐢ䈇ታ㛎㊁䉕⏕଻䈚䈩䇮䈠䈱ਛ䈪ᄙ᭽䈭⋡䈮䉋䉎តᩏᵴേ䉕䉁䈝䉇䈦䈩䉂䉋䈉䈪䈲䈭䈇䈎䇯䈖䉏䈏䇮ᧄ䊐䉤䊷䊤䊛䈱ᄢ䈐䈭⋡⊛䈪䈅䉎䇯㩷଀䈋䈳䇮ᖱႎ䈱౒᦭ൻ䈱䊝䊂䊦䈫䈚䈩䈅䉎䊈䉾䊃䊪䊷䉪ൻ䈱䊜䊥䉾䊃䇮䊂䊜䊥䉾䊃䇮䊥䉴䉪䈭䈬䈮䈧䈇䈩䇮⼏⺰䈜䉎䈖䈫䇯ᚗ䈇䈲䇮㓸ਛൻ䈚䈢ᖱႎᯏ᭴䈱ሽ࿷䈏䈬䈱䉋䈉䈭䊜䊥䉾䊃䊂䊜䊥䉾䊃䇮䊥䉴䉪䉕ᜬ䈧䈎䉕వ䈱䊈䉾䊃䊪䊷䉪ൻ䈫ኻ⟎䈚䈩⼏⺰䈜䉎䈖䈫䇯Ṽὼ䈫䈲䈚䈩䈇䈩䇮ᒻ䈮䈲䈭䉌䈭䈇䈏䇮౒᦭䈜䉎䈖䈫䈪ᣇะᕈ䉕⷗䈧䈔䈉䉎䉋䈉䈭តᩏᵴേ䈫䈚䈩䈱䊐䉤䊷䊤䊛䈏ሽ࿷䈜䉎䈖䈫䈏䇮ᰴ䈱ౕ૕⊛䈭䉺䊷䉭䉾䊃䈱᡹⇛䉕⠨䈋䉎㓙䈮䇮ᄢ䈐䈭ജ䈫䈭䉎䈫⠨䈋䉎㩷䇸ో૕䈱⷗ข䉍࿑䇹㩷㩷䉝䉳䉝䈏䉖䊈䉾䊃䊪䊷䉪ᒻᚑᔅ㗇ⷐ⚛䈲એਅ䈱ੑ䈧䈪䈅䉎䇯㩷㩷 䋱㩷 ⋧੕䈱ᔅⷐᕈ㩷㩷 䋲㩷 ᱜᒰൻ䈜䉎ℂ⺰㩷㩷䉝䉳䉝䈏䉖ᖱႎ䊈䉾䊃䊪䊷䉪᭴ᗐ䈱᭴▽䈲䇮㪉㪇㪇㪋 ᐕ䈎䉌ឭ໒䈚䈩ᵴേ䈚䈩䈐䈩䈍䉍䇮㪉㪇㪇㪎 ᐕ䈱቟୚䊶᷷ኅቲળ⺣䈱ਛ䈪੤䉒䈘䉏䈢ᣣਛකቇ᭴ᗐ䈮䈍䈇䈩䇮ታ⾰⊛䈮䉴䉺䊷䊃䈚䈢䈏䇮䈠䈱ਛ䈪⫾Ⓧ䈘䉏䈩䈐䈢䉝䉳䉝䈏䉖䊈䉾䊃䊪䊷䉪䈮䈧䈇䈩䈱ో૕᭴ᗐ䈱䊙䊃䊥䉾䉪䉴䈎䉌ㅀ䈼䉎䇯㩷㩷䊙䊃䊥䉾䉪䈫䈚䈩䈲䇮䉁䈝⃻⁁⹺⼂䈱䈢䉄䈱䇮❑ᮮਔᣇ䈱ⷰὐ䈏䈅䉎䇯㩷㩷ᮮᣇะ䈱ゲ䈫䈚䈩䈲㩷 ක≮䊶⎇ⓥ䊶↥ᬺ䋨ක⮎ຠ㐿⊒䋩䈱౞Ⅳ䉕ୄ⍑䈚䈢䉝䉳䉝ੱ䈱౒᦭ᕈ䉕↢䈎䈚䈢䈏䉖⎇ⓥ䉿䊷䊦䈱㐿⊒㩷 ᳃ᣖ∉ቇ䉇㩷 ᳃ᣖ䉭䊉䊛䈫䈇䈉᳓ᐔ䈱ᐢ䈏䉍䉕㩷 䈬䈉᝝䉌䈋䉎䈎䉝䉳䉝䈫䈇䈉ᷙᴋ䈫䈚䈢ᐢ䈏䉍䈱ਛ䈪䈲ᄢ䈐䈭⺖㗴䈪䈅䉎䇯㩷㩷❑ᣇะ䈱ゲ䈫䈚䈩䈲䇮ੑ䈧䈱ᣇะᕈ䈮䈧䈇䈩⠨ᘦ䈜䈼䈐䈪䈅䉎䇯㩷㪫㫆㫇㩷㪻㫆㫎㫅㩷 ဳ㩷 䊊䉟䊧䊔䊦䊐䉤䊷䊤䊛䇸䈅䉎䈼䈐䇹ᆫ⺰㩷 ⍮ᕺ䈫ജ㩷 㩷㪙㫆㫋㫋㫆㫄㩷㫌㫇㩷 ဳ㩷 㩷 ⥃ᐥ䈫↢ᵴ⠌ᘠ䈮㑐䈜䉎ᖱႎ䈱෼㓸䈫ᵹㅢ㩷 㩷䉝䉳䉝䈫䈇䈉䊐䉞䊷䊦䊄䈪䇸䈭䈮䈏䈪䈐䉎䈎䇹䈫䈇䈉 㪝㪼㪸㫊㫀㪹㫀㫃㫀㫋㫐㩷 㪪㫋㫌㪻㫐㩷㩷䉝䉳䉝䈏䉖䊐䉤䊷䊤䊛䈲䇮䉋䉍ᱜ⏕䈮䉋䉍ᣧ䈒࿖㓙␠ળ䈮䈍䈔䉎䇮䉝䉳䉝㑐ㅪ䈱ᖱႎ䉕౉ᚻ䈜䉎䈢䉄䇮䊪䉲䊮䊃䊮䌄䌃䊶䊔䉶䉴䉻䈮䈅䉎䇮䉲䊮䉪䉺䊮䉪䇸㪮㪸㫊㪿㫀㫅㪾㫋㫆㫅㩷㪚㫆㫉㪼䇹㪿㫋㫋㫇㪑㪆㪆㫎㪺㫆㫉㪼㪅㪺㫆㫄㩷䈮දജ䉕䈚䈩䈇䈢䈣䈇䈩䈇䉁䈜䇯㩷 㩷 㩷Daily News

Advanced

Readers

All Free Articles

Top 10 Last Month

ScienceShots

Daily News Archive

About ScienceNOW

Home > News > ScienceInsider > Japanese Cancer Scientists Plan Asia-Pacific Research Network

SearchSearchSubscribe to this blog's feed
Feedback or tips

Categories
Bioweapons Lab "Stand Down" Letter Posted | Main | Atom Smasher On the Mend

Asia (9)Biomedicine (31)FEBRUARY 9, 2009

Japanese Cancer Scientists Plan Asia-Pacific Research Network
TOKYO—International health organizations have long recognized the devastating impact of infectious
diseases such as HIV/AIDS, malaria, and tuberculosis on developing countries. Now researchers are also

Budget (24)Defense (12)Education (16)sounding an alarm about the burdens of non-communicable diseases, particularly cancer. Japanese

Energy (7)researchers hope to highlight the problem and contribute to solutions by bringing together labs andEnvironment/Climate (22)hospitals throughout Asia into a cancer research network.

Europe (27)

"Cancer is expected to become more serious in middle- and low-income countries, yet it has not attracted

Obama Transition (37)sufficient global attention," Hajime Inoue, director of international cooperation for Japan's ministry of health

Physical Science (10)told the Third Cancer Asia Forum on 7 February here.

Space (10)Inoue noted that improving child and maternal health and halting the spread of infectious diseases areamong the United Nations Millennium Development Goals. But he pointed to studies indicating that overTechnology (5)Weblogs

70% of worldwide cancer deaths in 2007 occured in low- and middle-income countries and, that in 2015,
more deaths will likely result from tobacco-related diseases such as cancer, than from HIV/AIDS.

Monthly Archives

While cancer is a global problem, solutions have to be local. "The epidemiology of cancer in Asia and in the

February 2009 (30)West is very different," said Hideyuki Akaza, a urologist at University of Tsukuba in Japan. He explained

January 2009 (63)that because of genetic and dietary factors, certain cancers are more prevalent in Asia than in the West

December 2008 (63)and the response to treatment varies. Yet limited clinical trial data has hindered the development ofevidence-based guidelines for cancer care in Asia, he said.

November 2008 (18)

To fill the gap, researchers are eyeing a network modeled on the United States' National Comprehensive
Cancer Network (NCCN), through which 21 leading American cancer centers collaborate to conduct
research and develop clinical care guidelines. Akaza and others hope a similar Asian network will grow out

Recently on ScienceNOWof the 20th Asia Pacific Cancer Conference to be held in Tsukuba from 12 to 14 November. Akaza, who is

Novel HIV-Fighting Method Finally Gelspresident of the conference, already has groups working on proposals for advancing cancer prevention,

One Giant Leap for Robot-Kinddiagnosis, and treatment and he believes that can set the stage for a more formal ongoing effort.

Flu: It's the Humidity. Absolutely

NCCN makes selected clinical practice guidelines available in Chinese, Korean, and Japanese. It also

Climate Change Is Friend and Foe to Ozone Layerholds meetings to discuss cancer issuse throughout Asia and the Middle East. But rather than tag along on

The Sound of Six-Legged Majesty

an American initiative, "It's important that people in Asia take action," says Akaza.
—Dennis Normile
Posted on February 9, 2009 2:38 PM in Asia, Biomedicine | Permalink | Comments (0) | TrackBacks (0)Blogroll
Science Progress

0 TrackBacks

Dot Earth

Listed below are links to blogs that reference this entry: Japanese Cancer Scientists Plan Asia-PacificResearch Network.

Effect Measure

TrackBack URL for this entry: http://blogs.sciencemag.org/cgi-bin/mt/mt-tb.cgi/2702

Prometheus
The Intersection
Space Politics

Leave a commentThanks for your feedback. Please keep it polite and to the point.
Sign in to comment on this entry, or comment anonymously.

ClimateScienceWatch
Reality Base
Secrecy News
Science Careers Blog

Magazine | News | Signaling | Careers | Multimedia | Collections | Help | Site Map | RSS
Subscribe | Feedback | Privacy / Legal | About Us | Advertise With Us | Contact Us© 2008 American Association for the Advancement of Science. All Rights Reserved.
AAAS is a partner of HINARI, AGORA, PatientInform, CrossRef, and COUNTER.